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PREFACE
This body of work was produced over 2 years during which I had the fortune to 
work for Professor Kenneth McColl, a distinguished authority in 
gastroenterology and expert in the field o ïHelicobacter pylori infection. Initially 
I felt daunted and was unsure whether I had the qualities required for research. 
However, I received tremendous encouragement and quickly came to cherish the 
unique fellowship that is founded through the pursuit of a common research goal.
My work provided an opportunity to study basic science, perform laboratory 
bench work and engage in clinical studies. Some of the work has been published 
and reprints are submitted with this thesis. In all areas T have learned to 
appreciate the value of thorough preparation and attention to detail.
Collaboration with colleagues was necessaiy and this is described in the 
acknowledgements. Except where stated, the work presented was carried out by 
myself.
The writing of this thesis is entirely my own work.
ABSTRACT
In 1975, Correa’s original hypothesis for gastric carcinogenesis proposed that 
atrophic gastritis leads to achlorhydria and secondary colonisation of the stomach 
with nitrosating bacteria. These organisms reduce dietary nitrate to nitrite, then 
catalyse the synthesis of potentially carcinogenic N-nitroso compounds (NOC) 
from nitrite and secondary amines present in gastric juice.
Since then, significant advances have been made in our understanding of gastric 
physiology which are also relevant to our understanding of gastric carcinogenesis. 
Helicobacter pylori (H. pylori ) infection is now a recognised risk factor for 
gastric carcinogenesis. If it produces a pangastritis, there is an associated degree 
of gland-loss (atrophy) of the acid-secreting body of the stomach. Atrophic 
gastritis is a precursor of the development of gastric cancer. H. pylori infection 
also lowers levels of vitamin C, which is secreted into and concentrated within 
gastric juice. The synthesis of NOC is inhibited by vitamin C.
Advances in the treatment of acid-related disorders have resulted in the 
prescription of increasingly potent inhibitors of acid secretion. The proton pump 
inhibitors (PPTs) render H. pylori infected subjects achlorhydric from,one dose to 
the next. They also promote the development of a pangastritis. Whether these 
effects are harmflil in the long term remains hotly debated. Two recent reports 
suggest that long term PPI therapy does lead to development of moderate-severe 
atrophy of the gastric body in -18%  of H. pylori infected subjects, compared to 0 
- 2% of no-infected subjects, thereby placing these patients at risk of gastric
4cancer. There are great concerns that the falling incidence of gastric cancer in the 
developed world may be reversed by widespread prescription of these agents.
How PPTs produce gastric atrophy in H. pylori infected patients remains to be 
elucidated. This thesis postulates that, in the presence of co-existing H. pylori 
infection, drug-induced achlorhydria alters the intragastric environment in a way 
that will facilitate bacterial synthesis of carcinogenic NOC which in turn may 
damage gastric epithelial stem cell DNA.
The thesis begins by re-examining the roles of nitrate, nitrite and vitamin C in 
man. The enterosalivary recirculation of ingested nitrate is described, whereby 
dietary nitrate is reduced to nitrite in saliva to provide the main source of nitrite 
to the upper GI tract. The important chemical interactions between nitrite and 
ascorbic acid in vitro are described with reference to NOC synthesis. NOC 
synthesis is promoted by a high nitrite ; ascorbic acid ratio. The in vivo 
interactions between saliva nitrite and gastric ascorbic acid are speculated upon 
and the potential effects of PPI-induced achlorhydria and H. pylori infection on 
these interactions are considered.
To begin, novel studies infused nitrite into the acid stomach to mimic salivary 
nitrite influx following a nitrate meal. These studies demonstrate for the first time 
in vivo the interaction between nitrite and vitamin C in the gastric lumen. Gastric 
juice ascorbic acid is depleted and in the process is converted to dehydroascorbic 
acid. Nitrite is lost from solution - presumably as nitric oxide. These novel studies 
were repeated, replacing the nitrite infusion with a solution of nitrate to mimic the
effects of ingesting a portion o f lettuce. These studies confirm that ingestion of 
nitrate leads to elevation of saliva nitrite levels via the process of enterosalivary 
recirculation. They reveal that on meeting acid gastric juice, saliva nitrite is lost 
(presumably as nitric oxide gas) and ascorbic acid levels are depleted. This novel 
in vivo observation will occur where saliva and gastric juice first meet; namely the 
gastro-oesophageal junction. The role of nitric oxide at the gastro-oesophageal 
junction is speculated upon.
Studies focus on the process of enterosalivaiy recirculation of ingested nitrate. 
Oral bacteria generate nitrite from saliva nitrate within the mouth. Two groups 
are studied to examine whether the presence or absence of natural teeth is of 
importance to this process. The saliva nitrite levels generated in each group of 
subjects following the standard nitrate meal are similar, suggesting that bacteria 
resident in the dorsum of the tongue may be more important than those in 
gingival crevices. The effect o f antibiotics on the enterosalivary recirculation of 
nitrate is then assessed. The antibiotics produced an effect in one subject only. 
Fasting nitrite levels in saliva and gastric juice became undetectable and did not 
rise following the nitrate meal. In the absence of nitrite, gastric juice ascorbic acid 
levels were preserved. It was concluded that oral bacteria are of prime 
importance in generation of nitrite. The effects of antibiotics on synthesis of nitric 
oxide within the gastric lumen are speculated upon.
The effect of prolonged acid inhibition on the chemistry of nitrite and vitamin C is 
then examined. Subjects are studied following a 4 week course of omeprazole 
40mg daily. They are studied 2 hours following the last dose of the drug, when all
subjects are achlorhydric. Omeprazole raised median fasting gastric nitrite and 
lowered fasting gastric ascorbic acid to significant degrees. After the nitrate meal 
gastric nitrite levels were markedly increased. In H. pylori infected subjects, 
omeprazole also decreased total vitamin C levels in both gastric juice and serum. 
These changes in combination would facilitate bacterial synthesis of NOC. The 
reason for the elevated gastric nitrite is considered and that the chemical stability 
of nitrite at neutral pH is suggested as the main factor. In subjects with H. pylori 
infection, activated mucosal nitric oxide synthase is discounted as an additional 
source.
The studies conclude by examining whether the greater acid inhibition produced 
by PPI therapy in H. pylori +ve versus -ve subjects is indeed accompanied by 
more profound changes in the intragastric milieu which will facilitate bacterial 
synthesis of N-nitrosocompounds. During omeprazole, H. pylori +ve subjects 
recorded a higher intragastric pH and greater colonisation with non-H. pylori 
species. These bacteria included nitro sating species. H. pylori +ve subjects had 
higher intragastric nitrite levels following the nitrate meal. Omeprazole lowered 
intragastric vitamin C levels in H. pylori +ve subjects only. It is concluded that H. 
pylori +ve subjects on omeprazole experience disturbances in intragastric nitrite, 
vitamin C and bacterial colonisation that will facilitate bacterial N-nitrosation. 
This may place them at risk of future mutagenesis and carcinogenesis.
On the basis of these findings it is recommended that patients requiring long term 
PPI therapy have any co-existing H. pylori infection eradicated.
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CHAPTER 1
INTRODUCTION
16
1.1 Gastric carcinogenesis; the current hypothesis
Gastric cancer remains the second most common cancer in the world ( 1). 
Epidemiological studies have identified risk factors which include the presence of 
achlorhydria / hypochlorhydria (2,3) and diets which are high in nitrate or nitrite 
and low in vitamin C (4-10). More recently, Helicobacter pylori (El. pylori) 
infection has also been recognised as a major risk factor for cancer of the mid and 
distal stomach ( 11, 12).
The mechanism by which the above risk factors predispose to gastric 
carcinogenesis is not fully understood. In 1975 Correa published his original 
hypothesis for the development of gastric cancer. It required some modification in 
the following years but remains unchallenged (13). He proposes that the 
development of H. pylori-related atrophic gastritis and the associated 
hypochlorhydria permit colonisation of the gastric lumen by oropharyngeal 
bacteria. Some species o f bacteria have the ability to convert dietaiy nitrate to 
nitrite within the stomach and then facilitate the formation of N-nitroso 
compounds (NOC). These mutagenic compounds are generated in a nitrosation 
reaction between nitrite and other nitrogenous organic compounds (present in 
food and gastric juice). The levels of NOC generated are determined by both the 
amount of nitrite available (14,15) and the concentration of vitamin C, which 
inhibits nitrosation reactions (16-18). As the ratio of nitrite to vitamin C (ascorbic 
acid) increases, so the rate of nitrosation increases (19), NOC are recognised 
carcinogens in animals and can induce gastric carcinogenesis in rodents. To date 
there is no data directly incriminating NOC in gastric carcinogenesis in man (20).
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1.2 Recent developments relevant to gastric carcinogenesis
Since Correa modified his hypothesis in 1992 there have been several 
developments in the understanding of H. pylori infection and its influence on 
gastric physiology that are relevant to gastric carcinogenesis, H, pylori infection is 
widespread in the West o f Scotland, with a prevalence of 66% in the adult 
population, but the majority will remain unharmed. Infected subjects have an 
increased risk of developing peptic ulcers or cancer o f the mid and distal stomach 
(11,21). It is now recognised that the risk of developing pathology is related to 
the changes induced by the infection in the histology and function of the stomach; 
these changes are in turn determined by the characteristics of the organism and 
the host subject. In most H. pylori infected subjects the associated gastric 
inflammation is largely confined to the antrum. These subjects have normal or 
increased acid secretion and a proportion may develop a duodenal ulcer. There is 
little or no increased risk of gastric cancer. In other subjects, the associated 
inflammation involves the body and fundus of the stomach. Degrees of mucosal 
atrophy and impairment of acid secretion usually accompany this pattern of 
inflammation. This group of subjects with atrophic gastritis and hypochlorhydria 
is recognised to have an increased risk of developing cancer of the mid and distal 
stomach (22-25). Recent studies ha^e examined further the effects of H. pylori 
infection on gastric histology and function in a group of first-degree relatives of 
gastric cancer patients (26). It is well recognised that this group also has an 
increased risk of developing gastric cancer (27,28). These studies have shown 
that those first-degree relatives with current H. pylori infection have a much 
greater prevalence of acid hyposecretion and gastric atrophy than H. pylori 
infected controls. The prevalence of acid hyposecretion and gastric atrophy in
18
those first-degree relatives who were H. pylori negative was similar to the H. 
pylori negative control subjects. Therefore it appears that the combination of
H.pylori gastritis and hypochlorhydria may act synergistically to induce 
carcinogenesis -  as proposed by Correa. The genetic characteristics of the host 
subject also appear important. Additional effects produced by H. pylori infection 
within the stomach that are likely to be important for gastric carcinogenesis are:
1) Stimulation of increased epithelial DNA turnover
2) Stimulation o f free radical formation
3) Depletion of gastric juice ascorbic acid:
Vitamin C is actively secreted into and concentrated within the gastric juice of the 
healthy stomach (29). In fasting gastric juice it is present mainly in the reduced 
form of ascorbic acid (AA) (30,31). In subjects with H. pylori infection the 
concentration of vitamin C in gastric juice is subnormal and a significant 
proportion is the inactive oxidised form of dehydroascorbic acid (DHAA) (32- 
34). Hence acquiring H.pylori infection results in depletion of a factor important 
in preventing intragastric NOC formation.
A further development in our understanding of gastric physiology, with relevance 
to gastric carcinogenesis, comes via the increasingly widespread prescription of 
proton pump inhibitors (PPI) for the treatment of acid related disorders. 
Compared to their predecessors the H2 antagonists, PPI's suppress acid secretion
more effectively and provide superior symptom control over a 24-hour period. 
Several studies have addressed the effects of PPI-induced hypochlorhydria on 
gastric physiology. It is now recognised that these drugs alter the natural history 
of H. pylori gastritis. H. pylori gastritis that is predominantly confined to the
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gastric anti*um in the acid stomach becomes more diffuse in the presence of acid 
suppression. The infection spreads proximally to involve the gastric body and 
fundus to generate a pangastritis (35,36). This widespread inflammation persists 
despite discontinuing the drug. The consequences of this appear to be two fold. 
Firstly, subjects prescribed omeprazole are converted from having an antral 
predominant gastritis with a low risk of gastric cancer to having a pangastritis 
with associated impaired acid secretion. As a consequence, the degree of acid 
suppression achieved with PPI's is greater with co-existing H. pylori infection 
compared to H. pylori negative subjects. Such subjects experience sustained acid 
inhibition which renders them achlorhydric from one dose to the next (37). This is 
believed to arise as a result of the inflammation spreading to involve the acid- 
secreting body of the stomach. Various inflammatory mediators have been shown 
in vitro to exert additional inhibitoiy effects on gastric parietal cells. Secondly, 
concerns have arisen that with long term use, PPI-induced chronic inflammation 
in the body of the stomach may result in gland loss (atrophy of the gastric body) 
with the development of irreversible hypochlorhydria and an increased risk of 
developing gastric cancer (38). Concerns regarding the safety of drug-induced 
acid inhibition are not new. In the management of dyspepsia, H2 antagonists have
been used to induce hypochlorhydria for more than 20 years, yet the feared rise in 
incidence of gastric cancer has not materialised. This may be explained by the fact 
that these agents are less potent and fail to achieve complete inhibition of acid 
secretion over a 24-hour period. Therefore these agents do not alter the natural 
history of H. pylori gastritis to the same degree.
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To examine the safety of long term PPI therapy, workers have focused on 
whether it leads to the development of histological changes within the stomach 
that may predict progression to cancer. They have looked for the development of 
gastric atrophy - a recognised precursor to gastric cancer (22,23). Two studies 
have reported on the development of gastric body atrophy in patients with gastro- 
oesophageal reflux disease on long term PPI therapy and have stimulated great 
debate (39,40). Both studies used patients treated with anti-reflux surgery (ARS) 
as controls. Although the authors arrived at opposing conclusions, the study 
results were remarkably similar. Table 1.1 indicates the proportion of patients 
progressing to moderate or severe gastric body atrophy in the arms of each study.
Table 1.1
H. pylori negative 
3 - 5  yrs post surgery 3 - 5  yrs on omeprazole
Kuipers et al 0% 2%
Lundell et al 0% 0%
H. pylori positive
3 - 5  yrs post surgeiy 3 - 5  yrs on omeprazole
Kuipers et al 0% 18.6%
Lundell et al 4.5% 17.9%
Zero to 2% of H. pylori negative patients on long term omeprazole progressed to 
moderate-severe atrophy, which was similar to those treated with ARS. In 
contrast, approximately 18% of H. pylori positive subjects on long term 
omeprazole progressed to moderate-severe body atrophy, compared to 
approximately 4% of those treated with ARS. The exact mechanism for 
development of atrophy remains to be elucidated. However it is likely that the
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inflammation of the gastric body mucosa and the hypochlorhydria are important 
because in combination they begin to fulfil the conditions for NOC formation and 
carcinogenesis required by Correa's hypothesis,
1.3 The potential effects on gastric juice of drug-induced 
hypo/achlorhydria
From previously published work we can predict that PPI-induced 
hypochlorhydria or achlorhydria may favour the intragastric formation of NOC in 
several ways. To enable secondary bacterial colonisation of the stomach, the 
intragastric pH must remain above 4 (41). When the intragastric pH is >4 
colonisation of the stomach by bacteria capable of catalysing nitrosation can 
occur (42,43). In subjects with hypochlorhydria caused by atrophic gastritis 
(which is recognised to predispose to gastric cancer) levels of nitrite in gastric 
juice are elevated (44,45)and levels of ascorbic acid are depleted (31,45,46). 
Thus the nitrite:ascorbic acid ratio is altered to favour N-nitrosation; it is unclear 
to what extent this is due to the high pH or the gastritis.
PPI’s are among the most frequently used drugs worldwide and will render many 
patients achlorhydric. The suggestion that long term use may lead to an increased 
risk of developing gastric cancer has stimulated a renewed interest in the other 
key risk factors for gastric cancer and their role in the intragastric environment. 
These risk factors will be discussed in turn.
22
1.4 Review of the propeE'ties of nitrate, nitrite and vitamin C
1.4.1 DIETARY NITRATE
Over recent decades, there have been concerns that exposure to increasing levels 
of nitrate within the environment may represent an increased risk of cancer 
through the production of N-nitroso compounds (47). Nitrate levels have 
increased as a result of fliel combustion and sewage recycling but mainly through 
the increased use of nitrate based fertilisers. As a result, there has been increased 
nitrate accumulation in some root and leafy vegetables and leaching of nitrate into 
drinking water, where levels are monitored closely. Nitrates are also regularly 
used as food preservatives (E251, E252 represent sodium nitrate and potassium 
nitrate respectively).
The concern about dietaiy nitrate ( NO3" ) is not related to the ion itself but to
the fact that through the process of enterosalivary recirculation it can be
converted to nitrite ( NO2 " ) as follows. Upon ingestion nitrate is rapidly
absorbed from the upper small intestine and the majority excreted unchanged in 
the urine over the next 24 hours. However an estimated 25% of ingested nitrate 
undergoes enterosalivary recirculation (48). Nitrate is actively taken up from the 
circulation and concentrated within the salivary glands (49), then secreted within 
saliva. Upon entering the mouth, oral nitrate-reducing bacteria convert an 
estimated 20% of the nitrate to nitrite (50). Following a meal containing nitrate, 
salivary levels of nitrite will accumulate (51). With each post prandial swallow, 
therefore, large concentrations of nitrite are delivered within saliva to the
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stomach. Nitrite ( NO2 " ) represents a potential hazard as it can participate in
nitrosation reactions with other dietary constituents (such as secondary amines) 
to generate potentially carcinogenic N-nitroso compounds (see below).
1.4.2 NITRITE
In contrast to nitrate, environmental levels of nitrite are low. Small quantities of 
nitrite can be found in food that has been smoked or treated with preservatives 
(E249, E250 represent potassium nitrite and sodium nitrite respectively) but the 
main source of nitrite to the upper GI tract is ingested nitrate (52). Nitrite levels 
in serum are negligible. This is because it is avidly taken up by haemoglobin to 
produce methaemoglobin. (This is the mechanism of death in subjects who ingest 
large quantities of nitrite). Normally, haemoglobin is regenerated enzymatically as 
nitrite is released back into the circulation as nitrate.
Whereas nitrate ( NO3" ) is a stable ion, nitrite ( NO2 " ) is highly reactive at acid
pH. It decomposes in acidic solution to exist in complex equilibria with several 
nitrosating agents (53). These equilibria are shown below with nitrosating 
agents highlighted. X represents a catalyst of N-nitrosation reactions (such as
thiocyanate - SCN “ - which is abundant in saliva and gastric juice).
NO2” + EU ^  HNO2
HNO2 + H+ < --------- >  H2N0 2 '*' H2O + NO+
2HNO2 ^ ^  ^ 2^3  + H2O 
HNO2 + HX >  NOX + H2O
24
The relative importance of the various nitrosating agents is dependent on the 
ambient pH. Nitrosation reactions can proceed in the moderately hypochlorhydric 
stomach (pH 2 - 4) or in the profoundly achlorhydric stomach (pH>4) where they 
are catalysed by bacteria colonising the stomach (14,54), The maximal rate of 
nitrosation of amines occurs at pH 3.4 although in the presence of the catalyst 
thiocyanate the optimal pH is 2.5.
The nitrosating agents react with secondary amines to generate N-nitroso 
compounds (RgNNO). Seconda^ amines are abundant in food and gastric juice.
Examples of such reactions are illustrated below:
N0 + + R2NH ► R2NNO
N2O3 + R2NH ^  R2NNO
Ascorbic acid is a potent inhibitor of N-nitrosation reactions. If ascorbic acid is 
present it reacts with the nitrosating agents more rapidly than the nitrosating 
agents can react with the secondary amines, and converts them to non-nitrosating 
nitric oxide (NO). The ascorbic acid is oxidised to the inactive dehydroascorbic 
acid in the process e.g.:
2 H N 0 2 ^ _______> N 2 0 3   ^  2N 0 + 2.H2O
ascorbic acid dehydroascorbic acid
25
It has previously been demonstrated that in the healthy acid stomach (which 
contains vitamin C), nitrite is largely undetectable (55). Our own in vitro studies 
have confirmed that when nitrite is added to acidic gastric juice it is rapidly lost - 
presumably as nitric oxide. However, it is well established that nitrite is readily 
detected in achlorhydria (55-57). Our own in vitro studies have shown that if the 
pH of the acidic gastric juice is elevated to > 4, nitrite is readily recovered. If 
nitrite is present, it is available for N-nitrosation reactions.
1,4,3 VITAMIN C
Vitamin C is a water-soluble vitamin that plays a fundamental role in mechanisms 
of immune response and tissue protection. Man cannot synthesise vitamin C and 
requires a regular intake to maintain tissue levels. The vitamin is abundant in fresh 
fruit and vegetables and it is recognised that diets low in vitamin C are associated 
with an increased risk o f cancer (8-10). The vitamin takes two forms - ascorbic 
acid (AA) and dehydroascorbic acid (DHAA) which measured together constitute 
Total Vitamin C (TVC). In healthy subjects levels of vitamin C are greater within 
gastric juice than in serum. Once absorbed, vitamin C is actively secreted into and 
concentrated within the gastric juice of the healthy stomach (29). In fasting 
gastric juice it is present mainly in the reduced form of AA (30,31). Ascorbic acid 
is the active moiety of vitamin C. It is a strong reducing agent and at acid pH 
reacts rapidly with nitrite and other nitrosating agents. In the absence of oxygen, 
the reactions between ascorbic acid and the nitrosating agents proceed more 
quickly than the reactions between the nitrosating agents and secondary amines. 
Thereby, ascorbic acid can prevent formation of NOC within gastric juice by 
removing nitrite and the other nitrosating agents (58). As a consequence o f these
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reactions, AA is oxidised to DHAA while nitrite and nitrosating agents are 
converted to nitric oxide. Ascorbic acid also provides protection within the 
tissues by scavenging free radicals and preventing oxidative damage of DNA 
(59),
The efficacy of ascorbic acid is compromised in the presence of oxygen. The 
nitric oxide gas (NO) generated in the above reaction combines with Og to 
produce further nitrosating agents as follows (53):
2NO + O2 -------P- 2NO2
NO2 + NO ____ ^  N2O3
NO2 + NO2 —— —^  N2O4 
Thus the available supply of ascorbic acid is more likely to become exhausted. 
Once there is no further AA available, nitrosation reactions can proceed 
unhindered.
The efficacy of ascorbic acid is also affected by changes in pH. The molecule has 
2 pKa values (4.17 and 11.57). As the pH increases above 4.17, AA in solution is 
more susceptible to oxidation to DHAA (60). Previous in vii.ro studies have 
observed that vitamin C is unstable in neutral gastric juice and is irreversibly 
degraded to inactive metabolites (3 1,46).
The efficacy of ascorbic acid is also affected by co-existing H. pylori infection. In 
subjects with H. pylori infection the concentration of vitamin C in gastric juice is
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subnormal and a significant proportion is the inactive oxidised form of DHAA 
(32-34).
1.5 The potential effects on gastric juice of drug-indiiced hypo/achlorhydria 
and co-existing H. pylori infection
The incidence of cancer of the mid and distal stomach is falling in the developed 
world. However, the suggestion that one o f the most widely prescribed acid 
suppressing agents may predispose H. pylori infected patients to developing 
gastric cancer means that the chemistiy of the intragastric environment has a new 
found relevance. The interactions and reactions described above (which can result 
in NOC formation) will almost certainly be occurring in vivo within the stomach. 
These interactions may be the factors that facilitate the development of atrophic 
gastritis in the presence of drug-induced achlorhydria.
At present there is negligible information concerning the combined effect of H. 
pylori infection and PPI therapy on the factors recognised to be important in 
gastric carcinogenesis, namely 1 ) intragastric nitrite concentrations, 2) intragastric 
vitamin C concentrations and 3) colonisation of the stomach with nitrosating 
bacteria. There are theoretical reasons to believe that the interaction o f H. pylori 
gastritis and profound acid suppression with PPl's will accentuate each one of 
these predisposing factors. These reasons will be discussed in turn;
1.5.1 PPI therapy, H. pylori infection and intragastric nitrite 
Through the process of enterosalivaiy recirculation, there is a constant supply of 
nitrite to the stomach via saliva. Nitrite is highly reactive at acid pH. It is well
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established from in vitro work that in the presence of ascorbic acid nitrite is 
converted to nitric oxide gas. This reaction should theoretically occur in vivo 
when saliva nitrite meets acid gastric juice containing ascorbic acid. This reaction 
has been observed indirectly in a study by Lundberg et al (61). Nitric oxide was 
shown to accumulate in the gastric head space following a nitrate meal. Previous 
in vitro studies have shown that at pH > 3 nitrite begins to remain in solution. In 
patients with achlorhydria, nitrite is readily detected (55). This suggests that 
gastric nitrite levels should theoretically increase following the prescription of 
omeprazole. Lundberg et al also observed this indirectly in the same study. After 
the prescription of omeprazole, Lundberg could no longer detect nitric oxide in 
the head space following the nitrate meal. This suggests that the nitrite derived 
from the nitrate meal had remained in the gastric juice. A further mechanism 
whereby omeprazole may theoretically raise gastric nitrite levels is by facilitating 
secondary bacterial overgrowth of the stomach with nitrate reducing bacteria, 
which can convert ingested nitrate to nitrite within the stomach.
In patients with H. pylori infection, the inflamed gastric mucosa is a theoretically 
important additional source of nitrite. The infection stimulates mucosal nitric 
oxide synthase activity (62)and the nitric oxide may be converted to nitrate and 
nitrite within the gastric lumen. Hence the combination of drug-induced 
achlorhydria and H. pylori infection could result in elevated gastric juice nitrite 
levels as a result of the chemical stability of nitrite at high pH. The nitrite may 
arise from saliva, the inflamed gastric mucosa or from bacterial reduction of 
ingested nitrate (as is traditionally believed).
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1.5.2 PPI therapy, H. pylori infection and Vitamin C
Gastric juice ascorbic acid concentrations (the active form of vitamin C) are 
lowered in subjects with H. pylori infection (33)and also in patients with 
achlorhydria due to atrophic gastritis (45,46). In addition, it has been 
demonstrated that ascorbic acid is unstable in vitro at neutral pH hence it may no 
longer act as an efficient scavenger of nitrite in vivo (63). This suggests that the 
combination of PPI therapy and H. pylori infection is likely to result in profound 
depletion o f gastric juice ascorbic acid concentrations. This may then facilitate 
accumulation of intragastric nitrite.
1.5.3 PPI therapy, H. pylori infection and colonisation with nitrosating
bacteria
Colonisation of the human stomach with a mixed bacterial flora occurs with an 
intragastric pH>4. Recent studies have demonstrated that in those subjects with 
coexisting H. pylori infection the intragastric pH during PPI therapy is 
consistently higher (37). This higher intragastric pH will theoretically predispose 
them to greater colonisation with nitrosating bacteria.
In view of the above considerations it is important to document the effects of PPI 
therapy on intragastric nitrite, vitamin C and colonisation with nitrosating bacteria 
in subjects with H. pylori infection. If PPI therapy induces the changes in the 
intragastric environment predicted above, it may facilitate bacterial synthesis of 
N-nitrosocompounds.
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Although there is a body of evidence supporting the safety of long term PPI 
therapy, it is important to consider that these toxicology studies were performed 
on laboratory animals not infected with H. pylori. Different results may arise in 
humans due to their high prevalence of H. pylori infection.
1.6 Aims and hypothesis to be tested
The hypothesis being tested is that PPI therapy in H. pylori infected patients will 
produce conditions predisposing to N-nitrosocompound formation and thus 
gastric carcinogenesis; in particular a) increased intragastric nitrite 
concentrations, b) low intragastric vitamin C concentrations and c) increased 
intragastric colonisation by nitrosating bacteria. We predict that these changes 
will be more profound with coexisting H. pylori infection. We also hypothesise 
that an important cause of the elevated nitrite concentration is induced nitric 
oxide synthase activity within the inflamed gastric mucosa. The hypothesis will be 
tested in the following way.
Volunteers will ingest a standard nitrate meal to mimic average dietary nitrate 
consumption and studies will;
1 ) Observe in vivo the interactions of nitrite and vitamin C
2) Study the effect of omeprazole therapy on the above interaction and record 
intragastric concentrations of nitrite. Vitamin C and bacterial colonisation 
in subjects with and without H. pylori infection.
3) Investigate the contribution of mucosal nitric oxide synthase activity to the 
production of intragastric nitrite in H. pylori positive and negative subjects.
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CHAPTER 2
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2.1 STUDY PROCEDURES
For all the studies performed, the procedures were uniform and are described 
below.
Assessing H. pylori status
If required, the Helicobacter pylori status of volunteers was determined by a 
urea breath test as previously described (64). Subjects presented after ^^ n 
overnight fast. They brushed their teeth and provided a baseline sample of breath 
for a CO2 level. They ingested 0.4 MBq ^^C-urea in 20mls Ensure (to slow gastric 
emptying). A second breath sample was provided 30 minutes later. If H. pylori 
infection was present, the organism’s urease enzyme converted the urea into 
ammonia and released the within CO2. The enrichment of breath CO2 with 
was determined by liquid scintillation counting.
Dietary restrictions
In view of the influence of ingested nitrate on salivary and gastric juice nitrite 
levels, all subjects were asked to avoid consuming foods rich in nitrate (such as 
leafy vegetables) in the 24 hours leading up to a study day.
Obtaining gastric juice samples
All studies requiring samples of gastric juice followed the same initial procedure. 
The volunteers presented after an overnight fast. The nasal passages and phai'ynx 
were anaesthetised with lignocaine spray and a 16F-nasogastric tube ( Anderson 
Inc., New York, NY) was passed into the most dependent part of the stomach.
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The residual gastric juice was aspirated and discarded unless bacterial counts 
were required. To confirm that the tube lay in the most dependent part of the 
stomach a water recovery test was performed (65). Fifty mis of water were 
introduced via the tube. One minute later an attempt was made to recover the 50 
mis.
Gastric juice pH measurements
The pH of gastric juice samples was determined immediately using a glass 
electrode.
Obtaining saliva samples
Subjects were asked to pool saliva within their mouths at intervals (dictated by 
each study protocol) then expectorate it into universal containers. It is recognised 
that insertion of a nasogastric tube stimulates salivary secretions. Therefore, in 
studies utilising a nasogastric tube, thirty minutes were allowed to elapse 
following tube insertion before any experiment commenced so that salivary flow 
could reach a steady state.
Obtaining blood samples
An intravenous cannula was sited in an antecubital fossa vein with a 3-way tap 
attached. This allowed repeated sample collection over the course of each study.
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2.2 ANALYSIS OF NITRATE, NITRITE AND VITAMIN C 
Nitrate analysis
It was originally planned to measure nitrate levels within samples of gastric juice, 
serum and saliva and observe the enterosalivary recirculation of the nitrate meal 
in its entirety. There were 3 options for sample analysis.
1. The method of nitrate analysis described by Tannenbaum et. al. (51) is based 
on High Pressure Liquid Chromatography (HPLC) of samples. Samples are 
injected into a stainless steel ion-exchange column containing cadmium. This 
reduces all nitrate ( NOs' ) in the sample to nitrite ( NO2' ). Thereafter, nitrite 
concentration is determined by the classical Griess reaction whereby the 
sample is mixed with sulphanilic acid and naphthylenediamine (the Griess 
reagents) in an acidic medium. This generates a colour change. The depth of 
colour produced is determined by the quantity of nitrite present and can be 
accurately measured with a colorimeter.
2. With advances in technology, a HPLC column designed specifically to detect 
nitrite and nitrate directly is now available.
3. A commercial kit is available which uses a bacterial nitrate reductase enzyme 
to convert nitrate ( NO3’ ) in the sample to nitrite ( NO2’ ). Thereafter the 
Greiss reagents are added (as above) to measure the nitrite for a final 
quantification.
Sample analysis using HPLC was attempted. Major difficulties were encountered 
in removing sediment and other impurities from the samples of saliva and gastric
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juice. These impurities caused problems with blockage in the filters and column of 
the HPLC system. When samples o f gastric juice were spiked with known 
quantities of nitrate and nitrite, several peaks were produced on chromatography. 
None of the peaks coincided with the aqueous nitrate and nitrite standards used 
for comparison. It was felt that further progress in developing our own HPLC 
assay of nitrate would be difficult and it was abandoned.
The kit assay for analysing nitrate utilised a bacterial nitrate reductase enzyme in 
place of a cadmium column to reduce the entire nitrate in the sample to nitrite. 
This had been validated for plasma, urine and tissue homogenates. It had never 
been used for measuring nitrate in saliva or gastric juice. The samples were 
prepared as follows. To clean the gastric juice, samples were spun in an 
ultracentrifuge at 30,000 rpm for 10 minutes. Saliva samples were spun in a 
minifuge at 7,000 rpm for 30 minutes, Serum collected for nitrate analysis was 
stored at -20^C and prepared in accordance with the instructions of the kit 
manufacturer. On thawing, 400pi of sample was centrifuged through a lOkd 
ultrafilter (‘Microcon 10’, Millipore (UK) Ltd.) to remove high molecular weight 
proteins.
Samples were pipetted into a 96 well plate and mixed with a reaction buffer 
comprising bacterial nitrate reductase, enzyme co-factors (NADPH, FAD), 
phosphate buffer (pH 7.5). The plate was left to incubate in the dark for 3 hours 
at 3TC. This reduced all the nitrate ( NO?' ) to nitrite ( NO2’ ). The samples were 
then mixed with the Griess reagents and colorometric analysis was performed 30 
minutes later using a 540nm filter.
36
Major difficulties were encountered in measuring nitrate in samples of saliva and 
gastric juice. This was attributed to the poor performance of the bacterial enzyme 
in the stored samples of saliva and gastric juice. Prior to storage these samples 
were alkalinised (see below) to prevent loss of nitrite. Consequently it proved 
difficult to return the pH of the stored samples to pH7.5 to facilitate enzyme 
reduction of nitrate within the sample. Nitrate levels in serum, on the other hand, 
were accurately recorded as predicted by the kit manufacturer. The rise in serum 
levels of nitrate following ingestion of the standard nitrate meal could be 
monitored and thereby the first phase of enterosalivary recirculation observed. 
Levels of nitrate ( NO 3” ) within saliva and gastric juice were of secondary 
importance to the studies compared to levels of nitrite ( NO2’ ).
Nitrite analysis
In order to measure nitrite levels in saliva and gastric juice, it is necessary to 
elevate the pH of the sample to render it stable. Workers have traditionally added 
alkali to the samples immediately following collection to ti-y to prevent loss of 
nitrite. Sobala et. al., for example, mixed 0.5ml of 0.5M NaOH with 1.5 ml 
gastric juice(45). In this series o f studies, small volumes of concentrated alkali 
were added to the samples to minimise problems of sample dilution as follows:
1 ml of saliva was mixed with 10pi 5.0M NaOH. 2ml of gastric juice were mixed 
with 100pi S.OMNaOH. Samples were stored at 4 '^C and analysed on the same 
day. Nitrite levels in saliva and gastric juice were shown to remain stable for up to 
1 week using this method.
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Samples of saliva and gastric juice were prepared as described above and 
analysed on 96 well microplates by addition of the Griess reagents. Colorometric 
analysis was performed 30 minutes after the addition of the Griess reagents using 
a 540nm filter.
Analysis of ascorbic acid and total vitamin C
In order to assay vitamin C it was important to consider the highly reactive nature 
o f ascorbic acid in the presence of nitrite and oxygen. This was especially relevant 
for assaying ascorbic acid in gastric juice. The methods previously reported were 
followed (29,66).
0.5 ml gastric juice was added to two test tubes. Each contained 0.5 ml equal 
volumes of 2 % metaphosphoric acid / 0.5 % sulfamic acid and one also 
contained 6 mg/ml dithiothreitol (DTT). Serum samples were prepared similarly 
except that 0.5 ml serum was added to two tubes containing 1.0ml of 2 % 
metaphosphoric acid only and one also contained 6mg/ml DTT. Upon collection 
samples were immediately placed in liquid nitrogen before transfer to storage at - 
80"C.
Metaphosphoric acid denatures protein prior to HI^LC, lowers the sample pH, 
and thus stabilises AA. Sulfamic acid removes any residual nitrite within the 
sample thus preventing it oxidising the ascorbic acid. The purpose of the DTT is 
to regenerate AA from any DHAA in the sample thereby allowing quantification 
of total vitamin C levels.
38
Samples were analysed within 4 weeks. Prior to analysis samples were thawed 
and centrifuged at lOOOg. 0.3 ml of the supernatant was removed and further 
centrifuged in a minifuge at 9000g. Serum and gastric juice AA and TVC levels 
were measured by high performance liquid chromatography using a method 
similar to that first published by Schorah.C.J. (29,66). The instrumentation 
comprised a Waters 501 pump, a Gilson 231 automated sample injector and an 
Electrochemical detector (Shimadzu L-ECD-6A) set at 350 mV and 0.2 pA. 
Ascorbic acid was measured using reverse phase ion-pair chromotography on a 
Waters C l8 0DS2 analytical column (4.6 x 160 mm); protected by an Uptight 
guard column (20 x 3 mm) hand-packed with LiChroprep RP-18. The mobile 
phase consisted of 0.1 M sodium acetate containing lOniM octylamine. The final 
pH was adjusted to 4.3 with glacial acetic acid. The flow rate was 0.5 ml/min and 
the retention time of AA was 3 min. An aqueous stock standard solution (1 
mg/ml) was prepared by adding 5mg AA to 5.0 ml DTT (3,5 mg/ml). Working 
standards of 5 and 10 pg/ml were prepared by taking aliquots of the stock 
standard solution (0.05, 0 .1ml) and making the volume up to 10 mi. These 
standards were prepared daily. The autosampler was programmed to inject 150 pi 
aliquots of standards, quality controls and samples with the first injection being a 
DTT solution (3.5 mg/ml) to remove oxidising sites on the column. Subsequent 
standards and samples were processed with standards occurring every eighth 
sample. The rapid oxidation of AA to DHAA was largely overcome by keeping 
samples as cold as possible during assay procedure. The mobile phase was 
prepared fresh for each assay and the sample run was restricted to no more than 
fifty samples inclusive of standards and quality controls. This assay had a lower 
limit of detection of 0.2pg/ml.
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CHEM ICALS
All chemicals used in the assays were obtained from Sigma-Adrich Chemical Co. 
Ltd, Poole, U.K. except sodium acetate (Analar grade ) which was obtained from 
BDH Ltd, Liverpool, U.K. and glacial acetic acid which was obtained from May 
& Baker Ltd, Dagenham, U.K. The water used throughout this work was distilled 
and deionised in a Lisons Fi-Streem still.
2.3 DATA ANALYSIS
The data were analysed using non-parametric statistical tests. The 1 sample 
Wilcoxon test was used for paired data. The Mann Whitney U test was used for 
non-paired data. The areas under the concentration - time profiles for increases in 
saliva nitrite and gastric nitrite were calculated using the trapezoid approximation 
and Spearman rank correlation coefficients were calculated as required.
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CHAPTER 3
NOVEL IN  VIVO STUDIES OF THE INTERACTION BETWEEN 
NITRITE AND VITAMIN C IN GASTRIC JU ICE AND THE 
INFLUENCE OF INTRAGASTRIC pH
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3.1 Introduction
The fate of dietary nitrate, ingested in foods such as leafy vegetables, has been 
well documented. Nitrate is absorbed in the upper intestine. 25% of the absorbed 
nitrate undergoes entero-salivaiy recirculation via the blood to the salivaiy glands 
where it is concentrated and secreted in saliva. In the mouth an estimated 20% of 
salivary nitrate is reduced to nitrite by the action of commensal bacteria resident 
on the dorsum of the tongue (50). With each swallow, therefore, nitrite is 
introduced to the acid environment of the stomach. Ingested nitrate is thereby the 
main source of nitrite to the upper GI tract (52). On entering the stomach saliva 
meets gastric juice containing ascorbic acid.
The chemical reactions described in chapter one dictate that when salivary nitrite 
meets acid gastric juice containing ascorbic acid, nitric oxide (NO) will be 
produced. Workers have recently identified and measured NO in the gastric head 
space of the acid stomach following ingestion of a portion of lettuce (61). The 
quantities encountered were far greater than those produced by vascular 
endothelium. It has previously been demonstrated that in the healthy acid 
stomach, nitrite is largely undetectable (55) and ascorbic acid is present in 
concentrations greater than those found in serum (46). These observations 
suggest that the presence of NO in the gastric head space is probably the result of 
the interaction between saliva nitrite and ascorbic acid in the acid stomach.
In the same study (61 ), Lundberg demonstrated that NO was undetectable in the 
gastric headspace following administration of omeprazole. It is well established 
that nitrite is readily detected in achlorhydric stomachs (55-57). This has been
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attributed to bacterial over-growth of the stomach and bacterial reduction of 
ingested nitrate to nitrite. However, nitrite is chemically stable at high pH. Our 
own in vitro studies have shown that if the pH of the acidic gastric juice is 
elevated to > 4, nitrite is readily recovered. This accumulation of nitrite cannot be 
explained by the action of bacteria. This suggests an alternative, purely chemical, 
explanation for elevated gastric nitrite in achlorhydric patients. Furthermore, the 
pKa of ascorbic acid is 4.17 at low pH. At pH values above this it is less effective 
as a reducing agent and the reaction with nitrite proceeds slowly. Therefore 
omeprazole therapy could lead to elevation of gastric nitrite via 3 possible 
mechanisms; secondary bacterial overgrowth, the chemical stability of nitrite at 
high pH, or the impaired efficacy of A A at high pFF
In order to investigate the in vivo interactions of nitrite and vitamin C we aimed 
to simulate the conditions of the healthy stomach by infusing physiological 
quantities of nitrite into the stomach to mimic the delivery of saliva nitrite 
following a nitrate meal. In order to investigate the effect of intragastric pH on 
these parameters, we studied subjects before and after administration of the 
proton pump inhibitor omeprazole.
3.2 Subjects and Methods
4 healthy asymptomatic volunteers were recruited. None had a previous histoi*y of 
gastrointestinal disease and none suffered from dyspepsia. This small number was 
chosen because we believed the elevation in gastric pH produced by omeprazole 
would produce a profound elevation in gastric juice nitrite, based on the findings 
of our in vitro experiments.
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The study took place on two separate days. On day 1, basal samples o f saliva and 
gastric juice were collected and the subjects fed potassium chloride (1ml of a 
ImM solution) as a control solution. Further samples were collected over 40 
minutes. A rest period of 30 minutes followed. Then subjects were fed a standard 
solution of sodium nitrite of a concentration similar to that previously recorded in 
human saliva (1ml of a lOmM solution). Further samples were collected at 1
minute, 5 minutes, 15 minutes and 30 minutes. Following this, the subjects were
supplied with 2 capsules of omeprazole 40 mg to take at 12 hours and then 3 
hours before their appointment for the second study day. This was to ensure an 
intragastric pH > 4. The above protocol was then repeated.
Safety
Overdose of nitrite leads to methaemoglobinaemia with cyanosis, dyspnoea and 
circulatoiy collapse. The concentration of nitrite administered was equivalent to 
that normally present in swallowed saliva following a standard meal: total dose 
0.69 mg.
Toxic Dose (oral) Human: 14 mg / kg (RTECS, 1992)
Lethal Dose (oral) Human: 71 mg / kg (RTECS, 1992) 
sodium nitrite solution (of concentration lOOOOpmol / litre)
690 mg in 1 litre = lOOOOpmol / litre 
1 ml of the above contains 690/1000 mg of sodium nitrite 
= 0.69 mg sodium nitrite
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3.3 Results (all values expressed as medians with range in parenthesis)
Study day I: Gastric pH was 1,2 (1.0 - 1.4) and remained unchanged following 
infusion of the solutions. Baseline saliva nitrite was l36pmol/L (3 1 - 262) and 
values remained similar for the duration of the experiment. Gastric juice nitrite 
was undetectable in all subjects at baseline and this remained the case after 
instillation of the control solution. Following instillation of the nitrite solution, 
levels rose markedly. At 1 minute post instillation, gastric nitrite concentration 
was 131 pmol/L (70 - 229) (figure 3.1) Thereafter, levels rapidly returned 
towards baseline such that at 15 minutes post instillation they were undetectable.
At baseline gastric juice total vitamin C (TVC) was 8.4pg/ml (3.3 - 11.8) and the 
ascorbic acid (AA) moiety was 7. Ipg/ml (0,6 - 11.4). Thus gastric juice vitamin 
C was predominantly in the active form with an AA TVC ratio of 0.84 (0.18 - 
0.97). Following instillation of the control solution, these values remained similar 
such that at 30 minutes post instillation, gastric TVC was 7.5pg/ml (3.8 - 13.2) 
and gastric AA 6.8pg/ml (0.7 - 12,4). Immediately following instillation of the 
nitrite solution, gastric AA levels fell markedly to 0.9pg/ml (0.5 - 5.1) whereas 
gastric TVC remained similar at 6.6pg/ml (5.1 - 7.9). As a result, the AATVC 
ratio also fell to 0.14 (0,09 - 0.65) (figures 3.2 and 3.3), Over the following 30 
minutes, gastric AA levels recovered and gastric TVC levels remained 
unchanged. Consequently at 30 minutes post instillation of the nitrite solution, the 
AA TVC ratio had returned towards baseline at 0.87 (0.19 - 0.98).
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Study day 2: Baseline samples were collected without difficulty but the 
remainder of the protocol was difficult to follow due to problems obtaining 
gastric juice. This was of particular relevance to vitamin C analysis as it was 
difficult to collect samples rapidly, introducing the possibility of inaccuracies in 
measurement. Omeprazole elevated the intragastric pH in all subjects to 6.4 (4.1 - 
7.2), Intragastric pH remained unchanged following instillation of the solutions 
and was 5.7 (5.1 - 7.2) at the end of the study. Saliva nitrite was 143pmol/L (63 - 
157) at baseline and was unchanged over the duration of the study, measuring 
94pmol/L (64 - 162) at the end of the study. These levels were similar to those 
recorded prior to omeprazole. At baseline, gastric nitrite levels were detectable in 
3 of the 4 subjects at 25pmol/L (9 - 65). Thus in the presence of hypochlorhydria, 
gastric nitrite levels were readily measurable. This remained the case for the 
duration of the study. Levels of nitrite again increased markedly following 
instillation of the nitrite solution (figure 3.4). At 1 minute post instillation, gastric 
nitrite was 159pmol/L (19 - 456). Thereafter, levels returned towards baseline.
Gastric juice was collected for analysis of vitamin C in 3 of the 4 subjects. At 
baseline, gastric TVC was 8,6pg/ml (3.2 - 22.3) and gastric AA was 3.8pg/ml 
(0.2 - 6.0), Thus gastric TVC values were similar to those in the acid stomach. 
However, gastric AA values at this elevated pH were lower than those in the acid 
stomach. This is reflected in the lower baseline AATVC ratio of 0.27 (0.08 - 
0.44). Thus in the presence of hypochlorhydria only 27% of the vitamin C was 
present in the active moiety compared to 87% in the acid stomach. Due to
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problems with sample collection over the remainder of the study, the accuracy of 
subsequent vitamin C measurements was questionable.
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3.4 Figure legends and figures
Figure 3.1: Effect of an intragastric infusion of nitrite on gastric juice nitrite 
levels in the acid stomach. 4 subjects were fed a standard solution of sodium 
nitrite of a concentration similar to that previously recorded in human saliva (1ml 
of a lOmM solution). A solution of potassium chloride (1ml of a ImM solution) 
was used as a control solution as a control solution. Gastric nitrite levels were 
recorded over time.
Figure 3.2: Effect of an intragastric infusion of nitrite on gastric juice AA levels 
in the acid stomach. 4 subjects were fed a standard solution of sodium nitrite of a 
concentration similar to that previously recorded in human saliva (1ml of a lOmM 
solution). A solution of potassium chloride (1ml of a ImM solution) was used as 
a control solution as a control solution. Gastric AA levels were recorded over 
time.
Figure 3.3: Effect of an intragastric infusion of nitrite on gastric juice TVC levels 
in the acid stomach. 4 subjects were fed a standard solution of sodium nitrite of a 
concentration similar to that previously recorded in human saliva (1ml of a lOniM 
solution). A solution o f potassium chloride (1ml of a ImM solution) was used as 
a control solution as a control solution. Gastric TVC levels were recorded over 
time.
Figure 3.4: Effect of an intragastric infusion of nitrite on gastric juice nitrite 
levels at pH>4. 4 subjects were fed a standard solution of sodium nitrite of a 
concentration similar to that previously recorded in human saliva (1ml of a lOmM 
solution). A solution of potassium chloride (1ml of a ImM solution) was used as 
a control solution as a control solution. Gastric nitrite levels were recorded over 
time.
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3.3 Effect of intragastric nitrite infusion on gastric ju ice total 
vitamin C at acid pH
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3.4 Effect of intragastric nitrite infusion on gastric nitrite
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3.5 Conclusions
As anticipated, saliva nitrite levels were unaffected by intragastric instillation of 
chloride or nitrite, In the acid stomach, gastric nitrite was undetectable and 
vitamin C was predominantly in the form of ascorbic acid. These findings are in 
keeping with previous reports. Following intragastric instillation of the inert 
potassium chloride, levels of nitrite and vitamin C were unaffected. Following the 
instillation of nitrite (to mimic influx of saliva nitrite following a nitrate meal), a 
dramatic rise in gastric nitrite was obseiwed. This coincided with a dramatic fall in 
gastric juice AA. Gastric TVC levels were unchanged and the predominant form 
of vitamin C was now dehydroascorbic acid (DHAA). This change in the 
composition of total vitamin C can be explained by the chemical interaction 
between nitrite and ascorbic acid which occurs when they meet at acid pH, Nitrite 
is converted to gaseous nitric oxide and ascorbic acid is oxidised to the inactive 
DHAA.
Over the following minutes, the ratio o f AA TVC recovered towards baseline. 
TVC levels were unchanged. This suggests that AA is being regenerated from the 
inactive DHAA. This would be in keeping with previous theories that the gastric 
mucosa is capable of recycling oxidised vitamin C.
Following omeprazole, intragastric pH was elevated in all subjects as anticipated. 
Unfortunately, due to the associated reduction in gastric juice volume that occurs 
in association with PPFs (67), it proved difficult to obtain all the required 
samples over a short period of time. From these limited observations on the effect 
of hypochlorhydria on gastric juice, we confirmed that gastric nitrite levels are
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elevated and remained so for the duration of the experiment. In addition, ascorbic 
acid levels are depleted and vitamin C is predominantly in the oxidised form of 
DHAA.
The remainder of the samples collected in this protocol could not be analysed 
with any assurance of accuracy. In the presence of hypochlorhydria, sample 
collection times should be dispersed to allow accumulation of sufficient volume of 
gastric juice to facilitate speedy collection and processing of samples.
Numerous previous studies have examined gastric nitrite and vitamin C levels, but 
always independently of one another (44,45,57,68-70). All these studies have 
examined single samples of fasting gastric juice only. From the earlier work on 
the pharmacology of ingested nitrate (48) and the recognition that dietary nitrate 
provides the main source of nitrite to the upper G1 tract (52) it is clear that 
measurements from fasting gastric juice do not reflect the true effects of exposure 
to nitrite. This novel dynamic study provides the first in vivo observation of the 
interaction between physiological doses o f nitrite and vitamin C within the healthy 
stomach. This provides vital new information with respect to the gastric 
physiology of two factors recognised to play a key role in gastric carcinogenesis.
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CHAPTER 4
THE EFFECTS OF DIETARY NITRATE ON LEVELS OF VITAMIN C 
AND NITRITE IN GASTRIC JUICE
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4.1 Introduction
By infusing physiological quantities of nitrite into the acid stomach we have 
obtained evidence of an important and previously unrecognised reaction 
occurring in vivo between saliva nitrite and gastric juice vitamin C, In this study, 
we wished to recreate the conditions present following the ingestion of nitrate 
containing foods and repeat these observations in a larger sample.
4.2 Subjects and Methods
Twenty healthy volunteers were studied; (7 male, 13 female), mean age 30 years 
(range 20 to 47). None had a previous history of gastrointestinal disease and none 
suffered from dyspepsia. T\\q\y Helicobacter pylori status was determined by a 
'^^C-urea breath test as previously described (64).
Subjects avoided eating leafy vegetables for 24 hours before presenting fasted on 
the morning of the study day. Basal samples of blood, saliva and gastric juice 
were collected and then the subjects were fed 2 mmoL of potassium nitrate which 
is equivalent to a standard portion of lettuce (61). Further samples were collected 
at intervals over the next 2 hours.
4.3 Results
The median intragastric pFl was 14(1.1 - 3.2). The pFI did not change following 
the intragastric infusion of nitrate.
The median fasting serum nitrate was 24pmol/L (12-  67), saliva nitrite 44jamol/L 
(0 - 306) and gastric nitrite was undetectable in 16 subjects and at very low levels
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in the other 4 (at 3, 5, 12, 12pmol/L respectively) . Following the intragastric 
administration of the nitrate meal, serum nitrate increased approximately 4 fold 
and peaked at 82j.imol/L (49 -131)  and salivary nitrite increased approximately 6 
fold, peaking at 262p.moi/L (5 - 939) (figure 4.1) Peak values for both 
parameters were recorded at 40 minutes post dosing. Despite this marked 
increase in salivary nitrite, the median gastric nitrite remained undetectable in 10 
of the subjects. In 10 of the subjects studied, gastric nitrite levels increased 
following the nitrate meal. When compared with the 10 subjects in whom nitrite 
remained undetectable, these subjects had a higher salivary nitrite, as measured by 
the area under the concentration-time curve {saliva nitrite auc 22285jumol/L/min 
(10595 - 102000) vs. 5020 (3145 - 8650), p < 0.001},
The median fasting serum AA was 3.2pg/ml (1.0-  6.0) and serum TVC 3.6pg/ml 
(1.1- 6.6). The fasting gastric juice AA was 3.8pg/ml (0.3 - 20.7) and gastric 
juice TVC 5.0pg/ml (1.2-21).  Fasting AA and TVC levels were therefore 
higher within the gastric juice than the serum although this failed to reach 
significance. In the serum of each subject virtually all the vitamin C was in the 
form of AA, whereas in the fasting gastric juice the median ratio of AA to TVC 
(AA/TVC ratio) was 0.76 (range 0.25 - 1.0). Following the intragastric 
administration of nitrate, there was no change in the serum levels of AA and 
TVC. However, the gastric juice AA levels fell and this coincided with the rise in 
salivai'y nitrite (figure 4.1). At 60 minutes post nitrate meal, gastric juice AA 
reached its nadir of 0.9pg/ml (0.4 - 31.8) compared with 3.8|_ig/ml (0.3 - 20.7) 
pre-dosing (p<0.05). By comparison, gastric juice TVC increased to 6,2pg/ml
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(2.0 - 32.0) at 60 minutes compared with S.Opg/ml (1.2 -21) pre-dosing 
(p<0.05). At 60 minutes after the nitrate meal, the gastric juice AA/TVC ratio 
was 0,2 (0.04 - 0.99) compared to 0.76 (0.25 - 1.0) pre-nitrate dosing (p<0.001). 
Over the subsequent 60 minutes the gastric juice AA concentration and gastric 
AA/TVC ratio gradually returned towards their original levels, and this coincided 
with the fall in saliva nitrite levels. At 120 minutes post dosing, gastric juice TVC 
was 6.0|ag/ml (1.7 - 33.2) which was significantly higher than the fasting value of 
5 .0pg/m l(1 .2-21)(p-0 .003).
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4.4 Figure legend and figure 
Figure 4.1:
Effect of standard nitrate meal on serum nitrate, saliva nitrite, gastric nitrite, 
gastric total vitamin C (TVC) and gastric ascorbic acid (AA) in all 20 subjects. 
Intragastric bolus of 2 mmol nitrate in 50 ml H2O introduced immediately 
following baseline (time zero) collections. Values are medians plus interquartile 
ranges. * indicates significantly different from value at time zero at p<0.05, ** 
p<0.001 and *** p<0 .01 .
57
Figure 4.1 : Effect of standard nitrate meal in the presence of acid 
nitrate meal
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4.5 Conclusions
This study examined the effects on saliva nitrite, gastric nitrite and gastric vitamin 
C o f ingesting a quantity of nitrate equivalent to that present in a salad meal, It 
sheds further light on the previously unrecognised interactions between salivary 
nitrite, gastric nitrite and vitamin C that occur in the acid stomach.
Under fasting conditions, nitrite was present in saliva but undetectable in gastric 
juice. Vitamin C was readily detectable in fasting gastric juice; its concentration 
was higher than in serum and it was mainly in the form of AA (AA/TVC ratio = 
0,76), The higher concentration of vitamin C in gastric juice compared to serum 
is consistent with previous reports (29,30,46), and is thought to be the result of 
active secretion of the vitamin into the gastric lumen.
Following intragastric infusion of the nitrate solution, salivary nitrite 
concentrations increased markedly peaking at 40 minutes post dosing. This rise in 
salivary nitrite following ingestion of nitrate is well recognised and is due to 
enterosalivai'y recirculation of nitrate and its reduction to nitrite by bacteria in the 
mouth (50,51), The increase in salivaiy nitrite and consequent increased delivery 
of nitrite to the stomach in swallowed saliva resulted in a rise in gastric nitrite in 
only half of the subjects. The subjects who showed this rise in gastric nitrite had 
significantly higher salivaiy concentrations of nitrite.
In all subjects, the rise in salivary nitrite concentration was mirrored by a marked 
fall in gastric juice AA concentration but no change in gastric juice TVC, This fall 
in gastric juice AA and absence of a consistent rise in gastric juice nitrite
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following the salivaiy nitrite load can be explained by the rapid reaction between 
saliva nitrite and gastric AA in the acidic stomach. At acid pH nitrite is unstable 
and it reacts with AA, with the former being converted to nitric oxide and the 
latter oxidised to DHAA (58). Nitric oxide has been shown to accumulate in the 
gastric head space following nitrate ingestion (61).
Following the nitrite induced conversion of gastric AA to DHAA, there was a 
later increase in the gastric juice TVC concentrations being most apparent at 2 
hours post nitrate dosing. This rise may indicate increased secretion of the 
vitamin into the gastric juice. Little is known about the regulation of vitamin C 
secretion by the gastric mucosa but our observation would be consistent with 
stimulation of the process by either a low level of gastric juice AA or high level of 
DHAA.
These changes In gastric juice levels of nitrite and AA in the acid stomach 
following a nitrate meal may be relevant to the role of dietary nitrate and vitamin 
C in the aetiology of gastric cancer. In subjects with a diet high in nitrate and low 
in vitamin C the gastric juice will contain significant concentrations of nitrite 
following a meal. This will arise due to a high salivaiy nitrite load and inadequate 
gastric juice AA to convert it to nitric oxide. The high salivary nitrite load will 
also further deplete gastric juice AA, converting it to inactive DHAA, The 
resulting combination of high gastric juice nitrite plus low AA will favour the 
generation of potentially carcinogenic NOC (19). Chemical nitrosation in the acid 
stomach is accelerated by the presence of thiocyanate (15,71), which is also 
secreted in saliva and is present in high levels in smokers (72). Such chemical
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nitrosation may be particularly important in the pathogenesis of cancers of the 
cardia or gastro-oesophageal junction which occur in the non-atrophic stomach 
(73) and are associated with smoking (74,75), Our studies have shown that saliva 
nitrite is the major source of gastric nitrite and therefore chemical nitrosation will 
occur predominantly where saliva meets acid gastric juice i,e, at the gastro- 
oesophageal junction and cardia.
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CHAPTER 5
THE EFFECTS OF DIETARY NITRATE AND PROLONGED 
OMEPRAZOLE THERAPY ON LEVELS OF VITAMIN C AND NITRITE 
IN GASTRIC JUICE
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5.1 Introduction
In chapter 3, we obtained preliminaiy data on the effects of drug-induced 
achlorhydria on gastric nitrite and vitamin C levels by infusing physiological 
quantities of nitrite into the stomach to mimic those conditions generated after a 
meal containing nitrate. In this study we aimed to collect further data on the 
interactions of nitrite and vitamin C in the presence of hypochlorhydria by 
examining the fate of a nitrate meal during a standard course of omeprazole (used 
to heal oesophagitis).
5.2 Subjects and Methods
The twenty healthy volunteers who participated in the previous study (in chapter 
4) were recruited.
After completing the first study day, subjects were prescribed a 4 week course of 
omeprazole 40mg daily and returned 2 hours following the final dose. After 
collection of basal samples, the standard nitrate meal (2mmol potassium nitrate) 
was introduced into the stomach and a protocol identical to the first study day 
was followed, Measurements obtained on omeprazole were compared with those 
obtained pre-omeprazole.
5.3 Results
All values are expressed as medians (range).
Omeprazole produced a profound rise in intragastric pH in all subjects. The 
median intragastric pH increased from 1.4 pre-omeprazole to 7,2 (3,5 - 8.5) on
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omeprazole, p<0,001. The median intragastric pH on omeprazole remained 
unchanged following infusion of the nitrate meal.
On omeprazole, the fasting serum nitrate and saliva nitrite were similar to the 
values pre-omeprazole at 27pmol/L (15 - 56) and 28pmol/L (6 - 297) 
respectively. However fasting gastric juice nitrite levels on omeprazole were 
elevated at 13 pmol/L (0 - 50) compared to the pre-omeprazole fasting levels of 
Opmol/L (0 - 12) (p= 0.001) (figure 5,1).
Following ingestion of the nitrate meal, the peak serum nitrate and saliva nitrite 
levels at 40 minutes post dosing were also similar to the pre-omeprazole values at 
79|umol/L (46 - 165) and 295pmol/L (145 - 1041) respectively. However there 
was a profound rise in gastric nitrite levels (figure 5.2). At 60 minutes post 
nitrate ingestion on omeprazole, gastric nitrite peaked at 154pmol/L (49 - 384) 
compared to Opmol/L (0 - 111) at the 60 minute point pre-omeprazole 
(p<0,001) (figure 5.1).
On omeprazole, the fasting serum levels of AA and TVC were similar to the 
values pre-omeprazole at 3.4pg/ml (1.1 - 6.4) and 3.4pg/ml (1.1 - 7.3) 
respectively. However, omeprazole produced a profound fall in fasting gastric 
juice AA levels from a median of S.S^ig/ml (0.3 - 20.7) pre-omeprazole to 
0.7pg/ml (0.2 - 10.9) on omeprazole (p<0.001)(figure 5.1), which was near the 
lower limit of detection. Gastric AA was undetectable in one subject. Fasting 
gastric juice TVC was also lower on omeprazole at 3,0pg/ml (0.8 - 11.3)
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compared to 5.0pmol/L (1.2 - 21.0) pre-omeprazole (p< 0.005). On omeprazole 
the median fasting gastric AA/TVC ratio was 0.34 (0.06 - 1.0) compared with 
0.76 (0.25 - 1.0) pre-omeprazole (p=0.001).
Following administration o f the nitrate meal, there was no change in the serum 
levels of AA and TVC. The median gastric juice AA level remained low 
throughout (figure 5.2). At 60 minutes post ingestion, gastric juice AA was 
0.5pg/ml (0.2 - 18.7) which was similar to the fasting level. Gastric juice TVC 
increased following the nitrate meal. At 60 minutes post ingestion, gastric juice 
TVC had increased from the fasting value of 3.0 (0.8 - 10.9) to 3.6pg/ml (1.4 - 
37.4) (p=0.019). Consequently at 60 minutes post ingestion the median gastric 
AA/TVC ratio was 0.18 (0.02 - 0.77) compared to a fasting ratio of 0,34 (0.06 -
1.0) (p<0 .001).
5.3.1 Helicobacter pylori status and nitrate, nitrite and vitamin C
O f the 20 subjects who completed the study, 9 had a positive '^C-urea breath test 
for FI. pylori and 11 had a negative breath test. When the results of H. pylori 
positive subjects were compared with those of H. pylori negative subjects both 
pre and on omeprazole, no significant differences were found with respect to any 
of the parameters measured. Flowever, when the effect of omeprazole therapy on 
the intragastric milieu and serum of each group was assessed, two key differences 
were obseiwed between FI. pylori positive and H. pylori negative subjects.
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(1) The marked depletion of gastric TVC on omeprazole was confined 
to H. pylori positive subjects (figure 5,3).
(2) In H. pylori positive subjects, fasting serum TVC levels fell on 
omeprazole by a median of 13% (range 0 - 3 3 % )  such that the median 
value of 3.2pg/ml (1.2 - 5,3) was significantly lower than the 
corresponding pre-omeprazole value of 4.3pg/ml (1.1- 6.0) (p =
0.013) (figure 5.4). In H. pylori negative subjects, omeprazole had no 
effect on serum TVC; median % change was 0% (range -28 to +45%). 
This difference between the two groups was significant (p=0.003).
5.3.2 Studies of the contribution of mucosal nitric oxide synthase to 
intragastric nitrite concentrations
On omeprazole, gastric nitrite levels are elevated. An additional mechanism 
behind the high levels of nitrite in H. pylori infected subjects may be the 
contribution of inducible Nitric Oxide Synthase (i-NOS). This enzyme is present 
in inflammatory cells such as neutrophils and macrophages and shows increased 
activity in the presence of H. pylori-associated inflammation (62). It generates 
nitric oxide in large quantities from the amino acid precursor L-arginine. The 
nitric oxide has a veiy short half-life and is rapidly oxidised to nitrite and nitrate 
within the tissues (76).
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If any of the nitric oxide generated within the gastric mucosa were to diffuse into 
the gastric juice, at acid pH it may lead to further production of nitric oxide gas 
whereas at neutral pH it may give rise to further nitrite within the lumen.
Methods
To evaluate any possible contribution of mucosal i-NOS to intragastric levels of 
nitrite, a representative H. pylori positive subject was chosen along with a 
representative H. pylori negative subject to act as a control. Each subject was 
prescribed 10 days o f omeprazole 40mg to elevate intragastric pH in order that 
any gastric juice nitrite arising from mucosal i-NOS would remain stable and 
detectable within the juice. The subjects presented 24 hours following the final 
dose o f omeprazole. A protocol identical to the previous studies was followed. 
The subjects presented fasted and basal samples of saliva, gastric juice and serum 
were collected prior to infLision of the test solution. However, instead of nitrate, a 
0.05mmol/kg L-arginine solution was infused down the nasogastric tube. The aim 
was to provide a quantity of precursor that could be utilised by mucosal i-NOS to 
generate nitric oxide and thereby give rise to nitrate and nitrite. Further samples 
were collected over a 90 minute period.
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Results
The results for each subject are presented below in tabular form (units - p.mol/L); 
Subject PW. H. pylori positive. 88kg.
time (minutes) 0 10 20 40 60 90
saliva nitrite 33 24 37 29 31 28
gastric nitrite 3 0 2 3 3 7
plasma nitrate 17 17 17 17 17 16
gastric pH 7.9 7.5 7.8 7.5 7.7 7.2
Subject WH. H. pylori negative. 66.5kg.
time (minutes) 0 10 20 40 60 90
saliva nitrite 65 79 63 67 73 48
gastric nitrite 2 5 8 6 9
plasma nitrate 15 16 17 16 16 16
gastric pH 3.5 3.3 2.7 2.4 3.6 5.4
The gastric pH of the H. pylori positive subject on omeprazole remained neutral 
for the duration of the experiment. Following infusion of the L-arginine solution, 
there was no change in serum levels of nitrate. Consequently, the nitrate 
availability to the salivary glands was unchanged and saliva nitrite levels were 
unchanged. In addition, gastric nitrite levels were unaffected.
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5.4 Figure legends and figures
Figure 5.1: Effect of omeprazole on fasting gastric nitrite, fasting gastric 
ascorbic acid and on gastric nitrite levels at 60 minutes following the intragastric 
administration of 2 mmol nitrate in 50ml H2O. The results of all 20 subjects are 
included.
Figure 5.2: Effect of standard nitrate meal, in the presence o f omeprazole- 
induced hypochlorhydria, on semm nitrate, saliva nitrite, gastric nitrite, gastric 
total vitamin C (TVC) and gastric ascorbic acid (AA) in all 20 subjects. 
Intragastric bolus of 2 mmol nitrate in 50 ml H2O introduced immediately 
following baseline (time zero) collections. Values are medians plus interquartile 
ranges. indicates significantly different compared to time zero at p<0.05.
Figure 5.3: Effect of standard nitrate meal on gastric total vitamin C (TVC) 
levels in 9 H. pylori positive and 11 H. pylori negative subjects before ”  and
on omeprazole. Intragastric bolus of 2 mmol nitrate in 50 ml H2O 
introduced immediately following baseline (time zero) collections. Values are 
medians plus interquartile ranges. indicates lower than corresponding pre­
omeprazole value at p<0 .02 .
Figure 5.4: Effect of 4 weeks treatment with omeprazole 40mg daily on fasting 
serum total vitamin C (TVC) levels in 9 H. pylori positive and 11 H. pylori 
negative subjects.
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Figure 5.2 : Effect of standard nitrate meal in presence of achlorhydria
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Figure 5.3 : Effect of omeprazole on gastric juice total vitamin C following a 
nitrate meal, according to H. pylori status
O)ZL
O
?
0
1  ro
O
nitrate meal
25 -I
20 -
15 -
10 -
5 -
H. pylori positive subjects
20
I
40 60
”T
80
~1~
100
minutes
Pre
On
120
nitrate meal
O)
o
Ü"C
To
CT3
CD
H. pylori negative subjects
20
—|-
40
"T"
60
“T
80
~T“
100 120
©  Pre 
OH
minutes
73
Figure 5.4; Effect of omeprazole on serum total vitamin C, according to H. 
pylori status
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5.5 Conclusions
The present studies indicates that drug-induced profound hypochlorhydria 
depletes intragastric AA concentrations and increases intragastric nitrite 
concentrations. These changes are apparent in the fasting state but are even more 
marked following ingestion of nitrate. In H. pylori positive subjects, drug-induced 
hypochlorhydria also lowers both gastric and serum TVC concentrations. 
Furthermore, the elevation of gastric nitrite that occurs in H. pylori positive 
subjects during omeprazole does not appear to be enhanced by the activity of 
mucosal i-NOS.
Treatment with omeprazole produced a marked rise in fasting intragastric pH and 
this was accompanied by changes in intragastric nitrite and vitamin C 
concentrations in both fasting and post nitrate meal samples.
The salivary nitrite concentrations on omeprazole were similar to those pre­
omeprazole. However in the fasting gastric juice, nitrite was detectable in 18 of 
the 20 subjects and its median concentration of 13f.tmol/L was significantly 
greater than the equivalent value of Opimol/L pre-omeprazole. Following the 
nitrate meal gastric nitrite levels rose markedly and peaked at a median value of 
154j.imol/L at 60 minutes which was also significantly greater than the equivalent 
value of 0 pmol/L pre-omeprazole. Previous studies have failed to agree on 
whether omeprazole produces a rise in fasting gastric juice nitrite (57,70,77). This 
study is the first to show a profound rise post prandially.
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What is the explanation for the marked increase in gastric nitrite levels on 
omeprazole? Workers have until now concluded that the high levels of gastric 
nitrite found in achlorhydric subjects are a consequence of the reduction of 
ingested nitrate within the stomach by bacteria colonising the achlorhydric 
stomach (69,78-80). This is possible. However, in this study the timing of the 
appearance of nitrite in the stomach following the nitrate load would indicate that 
the gastric nitrite was predominantly salivary in origin. Despite instilling the 
nitrate directly into the stomach there was no significant rise in gastric nitrite 
levels until nitrate had been absorbed, secreted into the saliva and converted to 
nitrite in the saliva. Thus the high levels of gastric juice nitrite on omeprazole can 
be explained by the nitrite in swallowed saliva remaining as nitrite within gastric 
juice. The persistence of swallowed nitrite in gastric juice during omeprazole but 
much less so pre-omeprazole can be explained by the fact that nitrite is stable at 
high pH but is converted to nitric oxide and other nitrogen oxides at low pH 
(15,61).
On omeprazole the great majority of vitamin C in lasting gastric juice was in the 
inactive oxidised form of DHAA. This is in keeping with a previous report (31). 
The reason why the great majority of the vitamin C in fasting gastric juice on 
omeprazole is in the inactive oxidised form is unclear. The pKa value of AA at 
this lower pH range is 4.17. As the pH increases above this value AA in solution 
is more susceptible to oxidation to DHAA (60), Other substances in gastric juice 
such as iron or copper may promote this oxidation of AA at neutral pH (63).
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On omeprazole, the gastric juice TVC concentration was reduced by 
approximately 50%. This could be due to impaired secretion of the vitamin by the 
gastric mucosa and/or destruction of the vitamin in gastric juice of high pH. 
Previous in vitro studies have observed that vitamin C is unstable in neutral 
gastric juice and is irreversibly degraded to inactive metabolites (31,46). It is also 
possible that bacteria colonising the achlorhydria gastric juice could utilise the 
vitamin for their own metabolism (81),
Influence of Helicobacter pylori status
We studied subjects with and without H pylori infection as the infection has been 
reported to impair the secretion of Vitamin C into gastric juice and to reduce the 
ratio of biologically active AA to inactive DHAA (32,33). Prior to commencing 
omeprazole, H. pylori positive subjects had a lower gastric TVC and a lower 
AA/TVC ratio but this did not reach significance, possibly due to the relatively 
small number of subjects in each group. The previously reported H. pylori- 
induced changes in gastric juice vitamin C have been most marked in subjects 
with H. pylori-induced atrophy where the hypochlorhydria will have contributed 
to the vitamin C abnormality (31). Our subjects were relatively young and 
unlikely to have atrophy.
On omeprazole the H. pylori positive and negative subjects were similar with 
respect to the depletion of gastric juice AA and elevation of gastric juice nitrite. 
However, our present study examined the subjects at 2 hours post dosing when 
gastric pH was markedly elevated in both groups of subjects. Previous studies 
have shown that pH on omeprazole remains markedly elevated over the entire 24
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hour period only in H. pylori positive subjects (82). Due to the influence of 
intragastric pH on nitrite and AA concentrations, it is therefore likely that H. 
pylori positive subjects on omeprazole will over the entire 24h period have a 
more markedly lowered gastric juice AA concentration and higher nitrite level 
than H. pylori negative on omeprazole.
The observation that gastric juice nitrite levels were similar in the H. pylori 
positive and negative subjects on omeprazole (in the presence of similar gastric 
pH and saliva nitrite levels) is of interest. Within the mucosa o f chronic gastritis 
the activity of inducible nitric oxide synthase is increased (62). The nitric oxide 
generated can undergo further oxidation to yield nitrate and nitrite (76). If the 
nitrite produced within the mucosa was contributing to gastric juice nitrite levels, 
it would remain stable and readily detectable in the gastric juice of H. pylori 
positive subjects at neutral pH This was tested by infusing L-arginine (the 
precursor of nitric oxide) into the stomach of a representative H. pylori positive 
and negative subject rendered hypochlorhydric with omeprazole. The 
introduction of L-arginine did not result in elevation of serum nitrate, saliva nitrite 
or gastric nitrite in either subject. These experiments demonstrate that although 
gastric mucosal i-NOS may be induced in the presence of H. pylori infection (62), 
it does not contribute to concentrations of nitrate within plasma nor nitrite within 
gastric juice. Therefore, the mucosa in chronic gastritis is contributing little or no 
nitrite to gastric nitrite levels.
The H. pylori positive and negative subjects did differ with respect to the effect of 
omeprazole on gastric juice TVC levels. The lowering of gastric juice TVC by
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omeprazole was confined to the H. pylori positive subjects. These differences in 
gastric juice vitamin C levels occurred despite a similar intragastric pH and similar 
gastric nitrite levels in each group and suggest that omeprazole has enhanced the 
negative effect of H. pylori infection on gastric mucosal secretion of vitamin C. 
This could be explained by the fact that on omeprazole the inflammation 
associated with H. pylori infection is more extensive, involving the body region of 
the stomach, thus disrupting the function of a greater area of mucosa.
The H. pylori positive and negative subjects also differed with respect to the 
effect of omeprazole on their serum TVC levels. In the H. pylori positive but not 
the negative subjects, omeprazole therapy resulted in a fall in fasting serum TVC 
levels. The reason for this is unclear but likely to be related to the observed 
depletion of vitamin C within the gastric juice of H. pylori positive subjects on 
omeprazole. The process depleting the fasting gastric juice vitamin C may also be 
destroying vitamin C ingested in the diet and thus reducing its bioavailability. 
Previous studies have observed that serum TVC is lower in subjects with gastric 
atrophy (44) and hypochlorhydria (45,46). This reduction in serum TVC in such 
subjects may be partly a consequence o f reduced bioavailability of dietaiy vitamin 
C and could also contribute to progression of gastric atrophy which is known to 
be more common in states of vitamin C deficiency (13). Our observation that 
omeprazole therapy lowers both gastric juice and systemic vitamin C levels in H. 
pylori positive subjects may be relevant to the report of accelerated development 
of atrophic gastritis in H. pylori positive subjects on omeprazole (39), Vitamin C 
is known to provide protection against DNA damage by free radicals which are 
produced in excess by the H. pylori infected mucosa (59).
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In summary, our studies indicate that drug-induced profound hypochlorhydria 
results in depletion of AA and accumulation of nitrite within the gastric juice and 
the elevation of nitrite is particularly marked following nitrate ingestion. This 
lowering of the ascorbic acid ; nitrite ratio is likely to predispose to N-nitroso 
compound formation. At the high pH achieved with omeprazole, chemically- 
catalysed nitrosation is unlikely to occur but formation of NOC could occur in the 
presence of metabolically active nitrosating bacteria within the stomach. Previous 
studies have confirmed omeprazole leads to colonisation of the stomach with 
bacteria (57,70) They are mainly oropharyngeal in origin and such organisms 
have been shown to catalyse NOC formation in vHro (83). H, pylori itself has 
veiy weak nitrosating ability (83).
There have been conflicting reports concerning the presence of NOC in gastric 
juice on omeprazole (57,70,77). This may be due to the technical difficulties of 
measuring these compounds in gastric juice in vivo and because of the wide 
spectrum of such compounds that may be formed. In addition, these studies have 
either reported on only H. pylori negative subjects (70) or failed to take account 
of H, pylori status (57,77). None o f the previous studies have been performed 
after a nitrate containing meal, which we show markedly increases the intragastric 
nitrite concentrations during omeprazole treatment. Further studies are required 
to examine the effect of pharmacologically-mediated hypochlorhydria on 
intragastric NOC concentrations. These studies should be performed in H. pylori 
positive as well as negative subjects, should include the effect of a nitrate
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containing meal and should also consider the vitamin C status o f the subjects 
being studied.
81
CHAPTER 6
STUDIES ON THE EFFECTS OF DENTAL STATUS, BACTERIA AND 
ANTIBIOTICS ON THE M ETABOLISM  OF DIETARY NITRATE
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6.1 Effect of dental status on the metabolism of dietary nitrate 
6.1.1 Introduction
Endogenous formation of N-nitrosocompounds from nitrite is thought to be an 
important factor in the pathogenesis of oesophageal and gastric cancer. Saliva is 
the major source of the nitrite that reaches the oesophagus. The nitrite is 
generated within the mouth by the action of commensal bacteria upon dietary 
nitrate, which is absorbed and secreted in saliva. An important determinant of the 
number of bacteria in the mouth is the presence of natural teeth. Edentulous 
patients with dentures have fewer oral bacteria than subjects retaining their own 
teeth (84). The presence of natural teeth is therefore likely to exert a major 
influence on the salivaiy nitrite level. Over the past 20 years the prevalence of 
oesophageal adenocarcinoma and cancer of the gastric cardia has markedly 
increased (85). The prevalence of edentulous subjects has markedly fallen over 
the same period and this may explain the rise in prevalence of cancer through 
increasing concentrations of nitrite in saliva. The purpose of this study was to 
compare the salivary nitrite concentrations in subjects with and without their own 
teeth.
6.1.2 Subjects and Methods
Volunteers were excluded if they had taken antibiotic therapy within the previous 
2 weeks or were taking any medication known to interfere with salivation.
20 volunteers were recruited. 11 subjects, mean age 70 (50 - 78), were 
edentulous and routinely placed their dentures in sterilising solution overnight. 9
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subjects, mean age 59 (50 - 71), had retained all their teeth and cleaned them 
regularly.
The study involved one visit only. Volunteers presented after an overnight fast. 
The subjects with dentures placed them in their mouths at least 2 hours before 
attending. Those with their own teeth brushed them in their usual manner at least 
2 hours before attending. A baseline sample of unstimulated saliva (for salivary 
nitrite) was collected. A standard nitrate meal of 2 mmoL potassium nitrate 
(equivalent to the nitrate content of a helping of lettuce) was then ingested. The 
mouth was rinsed out with water. Over the next 2 hours further samples of saliva 
were collected at 15 minute intervals.
6.1.3 Results
Baseline measurements of saliva nitrite were similar in the false teeth and natural 
teeth groups at 191 ^ mol/L (34 - 414) and 60|_imol/L (18 - 450) respectively.
Following ingestion of the standard nitrate meal, saliva nitrite levels increased 
markedly in all subjects to peak at 40 - 60 minutes post ingestion. Nitrite levels 
remained elevated for the remainder of the 2 hours of the study. The levels of 
nitrite recorded were particularly high as salivary flow was not stimulated. There 
was no difference between the levels of nitrite achieved following the standard 
nitrate meal in subjects with false teeth compared to those who retained their own 
teeth (figure 6 .1).
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6.1.4 Figure legend and figure
Figure 6.1 The effect of a standard nitrate meal (2mmol potassium nitrate in 
50 ml H2O) on saliva nitrite levels in subjects with false teeth (n=l 1) and 
natural teeth (n=9). Median values and interquartile range over 120 minutes 
from the time of ingestion are recorded.
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Figure 6.1a: Effect of nitrate meal on saliva nitrite levels (false teeth)
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Figure 6.1b: Effect of a nitrate meal on saliva nitrite levels (natural teeth)
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6.1.5 Conclusions
The presence of natural teeth does not appear to have a bearing on salivary nitrite 
levels. This is especially apparent in fasting salivaiy nitrite recordings but also 
seen following ingestion o f the standard nitrate meal. This suggests that bacterial 
colonisation o f the mouth does not depend on the presence o f natural teeth. This 
would be in keeping with reports suggesting that bacteria resident within the sulci 
on the dorsum of the tongue are of prime importance in the production of nitrite 
from ingested nitrate (86).
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6.2 Studies on effect of antibiotics on the metabolism of dietary nitrate in
the presence of achlorhydria.
6.2.1 Introduction
In patients with achlorhydria, gastric nitrite levels are high. It is believed that 
denitrifying bacteria colonise the stomach and generate nitrite from dietaiy nitrate 
via a bacterial nitrate reductase enzyme. However, we have already demonstrated 
in vitro that levels of nitrite will accumulate in the absence of acid as a result of 
its chemical stability at high pH. Therefore the accumulation of nitrite in 
hypochlorhydric gastric juice may arise through two possible mechanisms. We 
sought to examine the relative contribution of bacteria to gastric nitrite levels in 
the presence o f hypochlorhydria by prescribing a course of antibiotics,
6.2.2 Subjects and Methods
6 healthy volunteers who had no symptoms of dyspepsia were recruited. 3 were
H. pylori positive and 3 were H. pylori negative. Subjects were excluded if they 
had received antibiotics within the previous month or were known to have a 
penicillin allergy.
Subjects received a 10 day course of omeprazole 40 mg each morning in order to 
elevate intragastric pH. They reported fasted 24 hours after the last dose.
Baseline samples of saliva, blood and gastric juice were collected for saliva nitrite, 
serum nitrate and gastric juice pH, nitrite and vitamin C assays. A simulated salad 
meal, containing 2 mmoL potassium nitrate, was inftised through the nasogastric 
tube. Over the next 2 hours further samples of saliva, gastric juice and blood were
taken. Following this, subjects were given 6 further days o f omeprazole 40 mg 
along with amoxycillin 250 mg four times daily. Subjects returned after the first 
24 hours of antibiotics and then after completing the course for flirther 
measurements, On each occasion the above protocol was followed.
6.2.3 Results
1. Fate of the nitrate meal during omeprazole
At 24 hours after completing the 10 day course of omeprazole, the median 
intragastric pH was 4.7 (1.3 - 8.0), The gastric pH of the 3 H. pylori infected 
subjects was 7.2, 7.4, 8.0 respectively; compared to 1,3, 1.9, 2.2 in the 3 H. 
pylori negative subjects.
Basal saliva nitrite on omeprazole was 54pmol/L (20 - 163) and gastric juice 
nitrite was 2pmol/L (0 - 19). Following the nitrate meal, saliva nitrite levels 
increased to a peak of 304pmol/L (243 - 1225) at 40 minutes post ingestion. 
Gastric nitrite levels also increased significantly in all subjects to a peak value of 
64|Limol/L (3 - 176) at 60 minutes post ingestion, p=0.04, and they remained 
elevated for the remainder of the experiment.
Basal gastric TVC on omeprazole was 3.4pg/ml (1.2 - 8 .6) of which gastric AA 
comprised 2.9|ug/ml (0.6 - 8.4). Following ingestion of the nitrate meal, gastric 
TVC values were largely unchanged. Gastric A A levels decreased and were low 
for the remainder of the experiment. The gastric AATVC fell in turn from a basal
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value of 0.73 (0.33 - 1.0) to its nadir of 0.14 (0.08 - 0.87) at 60 minutes post 
ingestion, p=0.04.
2. Effect of antibiotic treatment on the fate of dietary nitrate during 
omeprazole
After completing the course of antibiotics, the study protocol was repeated and 
the results compared with those obtained prior to antibiotics. Basal saliva nitrite 
levels before and after completing the course of amoxycillin were similar at 
54pmol/L (20 - 163) and 36|.Lmol/L (24 - 144) respectively. The area under the 
saliva nitrite/time curve on omeprazole was calculated for each subject to 
compare saliva nitrite levels produced following the nitrate meal pre and post 
antibiotics. Following the course of antibiotics, the median saliva nitrite auc was 
lower but this failed to reach significance [26385]Limol/L.min (340 - 58480) 
versus 30440pmol/L.min (23790 - 88255)]. Basal gastric nitrite levels before and 
after antibiotics were similar at l,5|Limol/L (0 - 19) and 3|umol/L (0 - 8) 
respectively. The area under the gastric nitrite/time curve on omeprazole was 
calculated for each subject to compare gastric nitrite levels produced following 
the nitrate meal pre and post antibiotics. Following the course of antibiotics, the 
median gastric nitrite auc was also lower but this too failed to reach significance 
[1385pmol/L.min (65 - 8320) versus 5340|Limol/L.min (730 - 13520), p=0.93j.
Gastric vitamin C levels did not change significantly following the course of 
antibiotics although they tended to be higher. Median gastric TVC increased from
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3.4pg/ml (1.2 - 8 .6) to 4.9|Lig/ml (2.0 - 10.3), p^O.29, and median gastric AA 
increased from 2.9pg/ml (0.6 - 8.4) to 3.6|ag/ml (0,8 - 9.3), p=^0.83. Fasting 
gastric AA:TVC ratio was unchanged by the antibiotics at 0.73.
In the 6 individuals studied, the course of amoxycillin altered nitrite levels in only 
one subject (Subject X); but the effect was substantial (figure 6.2). Within 24 
hours of beginning the antibiotics, basal saliva nitrite levels were approximately 
50% lower. More significantly, levels did not rise following ingestion of the 
nitrate meal. Basal gastric nitrite levels were also more than 50% lower.
Following ingestion of the nitrate meal, gastric nitrite levels did not rise. These 
effects were greater still on day 17 after completing the full course of antibiotics; 
nitrite was undetectable in both saliva and gastric juice.
The course of antibiotics also had a bearing on gastric vitamin C levels following 
the nitrate meal as illustrated (figure 6.2) In the 2 previous studies, gastric TVC 
increased markedly following ingestion of nitrate. This rise in gastric TVC 
coincided with the marked influx of saliva nitrite. Following the course of 
antibiotics and depletion of saliva nitrite, gastric TVC levels remained steady 
following the nitrate meal. Gastric AA levels were low in the presence of 
achlorhydria and were not significantly changed following the course of 
antibiotics.
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6.2.4 Figure legend and figure
Figure 6.2: Summary of the effects of amoxycillin on saliva nitrite, gastric nitrite 
and gastric vitamin C in Subject X during drug-induced achlorhydria. Data from 
all 4 study days are displayed. On each study day, 2mmol potassium nitrate is 
ingested at time zero and measurements taken over the following 2 hours. Day 1 
is prior to omeprazole. Day 10 is during omeprazole. Day 11 is following 24hrs 
of amoxycillin during omeprazole, Day 17 is following 1 week of amoxycillin 
during omeprazole.
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Figure 6.2; Effects of amoxycillin on saliva nitrite, gastric nitrite and gastric 
vitamin C during drug-induced achlorhydria.
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6.2.5 Conclusions
The effect o f the course of amoxycillin on nitrite levels was disappointing with 
respect to the group as a whole. The great diversity of bacteria present in the 
orophaiynx and the presence of antibiotic resistant strains can explain this. 
However in one subject studied the amoxycillin clearly destroyed all the nitrate 
reducing bacteria in the oropharynx. This can be inferred from the dramatic 
absence of saliva nitrite within basal and post nitrate meal samples after a week of 
antibiotics. The antibiotics also effectively prevented the accumulation of nitrite 
within the achlorhydric stomach. However, this does not give any fluther clues as 
to the origin of nitrite in the achlorhydric stomach. The orophai^yngeal bacteria 
colonise the stomach during achlorhydria therefore antibiotics will destroy these 
bacteria regardless of where they lie. The results do emphasise the role of oral 
bacteria in generating a constant supply of nitrite to the upper GI tract.
In the absence on a saliva nitrite influx following the nitrate meal, gastric TVC 
and the gastric AA:TVC ratio were unchanged for the duration of the experiment. 
This contrasts with the rise in gastric TVC observed in the previous studies. This 
reinforces the effect of saliva nitrite on gastric juice AA levels and suggests that 
the influx of saliva nitrite may be a factor regulating gastric secretion of vitamin 
C,
These observations of the effect of amoxycillin on saliva nitrite may be of 
importance in the individual with a healthy acid stomach. If antibiotics reduce or 
prevent saliva nitrite production, then this will reduce or prevent nitric oxide
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generated at the gastro-oesophageal junction when saliva nitrite meets acid 
gastric juice. Nitric oxide is toxic to bacteria. It has been proposed that the nitric 
oxide production at the gastro-oesophageal junction is part of the host defences 
against bacterial infection (87). Therefore this side effect of antibiotics may partly 
explain the problems of GI infection secondai^ to antibiotic use.
A further key observation in this study was that at 23 hours after the last dose of 
omeprazole, the degree of acid suppression was greater in the 3 H. pylori infected 
subjects. They all remained achlorhydric, whereas the 3 H. pylori negative 
subjects had near normal gastric pH values. This is in keeping with previous 
reports (37), This suggests that any effects on the intragastric milieu created by 
drug-induced achlorhydria are likely to be more sustained in H, pylori-infected 
subjects.
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CHAPTER 7
W ILL H ELICOBACTER PYLO RI INFECTION INCREASE THE RISK 
OF DEVELOPING GASTRIC CANCER DURING LONG TERM  
OM EPRAZOLE?
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7.1 Introduction
In chapter 5 we obseived that during omeprazole treatment gastric juice vitamin 
C concentrations fell in H. pylori positive subjects but not in H. pylori negative 
subjects. Gastric nitrite levels were markedly elevated in both groups. Thus the 
ascorbic acid : nitrite ratios were lowered in both groups of subjects, increasing 
the nitrosating potential of the gastric juice. In that study we examined all 
subjects at 2 hours following their last dose of omeprazole, when the effects of 
the drug on acid secretion are maximal, and intragastric pH was >4 in both the H. 
pylori positive and negative subjects. It is now recognised that over a 24 hour 
period PPI therapy is much more likely to maintain an intragastric pH>4 in H. 
pylori positive subjects (82). We observed this first hand in chapter 6 . It is likely 
that H. pylori infected subjects taking a PPI will have a greater nitrosating 
potential. Any differences in the intragastric milieu (and nitrosating potential) that 
may exist between H. pylori positive and negative subjects arising as a 
consequence of drug-induced hypochlorhydria will therefore be most apparent 24 
hours after the last dose.
The clinical relevance of this is already apparent. There is growing concern that 
long term PPI therapy with co-existing H. pylori infection might increase the risk 
of gastric cancer. Kuipers et al reported that long term omeprazole therapy 
prescribed for GORD resulted in an increased prevalence of corpus atrophy in H. 
pylori infected subjects (39). The methodology of this study has since received 
criticism. Lundell et al recently re-examined this question and concluded that 
omeprazole produced no significant increase in corpus atrophy (40). However 
both studies showed a similar degree of accelerated progression to moderate or
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severe corpus atrophy in H. pylori positive subjects on omeprazole; 19% after 5 
years in the Kuipers study and 18% after 3 years in the Lundell study. 
Development of moderate or severe atrophy in H. pylori negative subjects on 
omeprazole and in H. pylori positives not given omeprazole was low in both 
studies at approximately 2%. The mechanism of the development of atrophic 
gastritis in H. pylori positive subjects on omeprazole remains to be elucidated.
We propose that the environment created within the lumen of the stomach may be 
responsible. In the present study we have examined intragastric pH, nitrite, 
vitamin C and bacterial counts in H. pylori positive and negative subjects before 
and during a course of omeprazole 40mg daily.
7.2 Subjects and M ethods
To facilitate the collection and immediate processing of samples, different groups 
of subjects were used for the bacteriology and biochemical studies,
29 healthy volunteers were recaiited to determine the effect of H. pylori status on 
bacterial colonisation during omeprazole therapy. The mean age of the H. pylori 
negative group was 27 (range 20 - 45) and that of the positive group 29 (21 - 
45). 32 different subjects (18 male, 14 female), mean age 35 (range 18 - 65) were 
recruited to examine the effects of H. pylori status on gastric nitrite and vitamin C 
during omeprazole. 5 of these subjects had dyspepsia and were recruited 
following upper GI endoscopy with CLO test and histology; 27 were healthy 
volunteers. All volunteers had their He/icobac/er pylori status determined by a 
‘^’C-urea breath test as previously described (64).
98
Design.
For the bacteriology study, subjects presented fasted on the morning of each 
study day. On day 1, gastric juice was sampled. Subjects were then prescribed a 6 
week course of omeprazole 40 mg daily. They returned 24 hours after the final 
dose for a repeat study. For the biochemical study, subjects avoided eating leafy 
vegetables for 24 hours before presenting fasted on the morning of each study 
day. On day 1, basal samples of blood, saliva and gastric juice were collected and 
then the subjects were fed 2 mmol of potassium nitrate, which is equivalent to a 
standard portion of lettuce (61). Further samples were collected at intervals over 
the next 2 hours. Subjects were then prescribed a 10-day course of omeprazole 
40 mg daily (it is recognised that the degree of acid suppression reaches steady 
state after 10 days) and returned 24 hours after the final dose for a repeat study. 
Subjects were asked to avoid antibiotic use for the duration of the studies.
Bacterial analysis
Ten ml of gastric aspirate was immediately inoculated into an anaerobic Bactec 
Blood Culture bottle (Beckton Dickinson, Oxford, UK) and transported to the 
laboratory. All samples were processed within 4 hours. The Bacteriologist was 
unaware of the treatment and FI, pylori status of the individual. On receipt, serial 
decimal dilutions up to 10'*^  o f the Blood Culture medium were made in Brain 
Fleart Infusion broth. 5 pi of each dilution was inoculated onto;
Bacitracin agar: blood agar base No. 2 (Oxoid Ltd, Basingstoke, UK) with 5% 
(v/v) defibrinated horse blood Haemophilus selectatab (Mast MS27A, Liverpool, 
UK) for isolation of Haemophilus spp.
99
5% blood agar; blood agar base No. 2 (Oxoid), with 5% (v/v) defibrinated horse 
blood and;
Cysteine Lactose Electrolyte deficient (C.L.E.D.) agar (Oxoid) for 
determination of aerobic bacterial Total Viable Count (BTVC.)
Gonococcus agar (Oxoid), with 5% (v/v) lysed horse blood, freeze dried 
antibiotic supplement for Neisseria gonorrhoea (Oxoid), yeast autolysate 
supplement (Oxoid) for isolation of Neisseria spp.
5% blood agar; blood agar base No, 2 (Oxoid), 5% (v/v) defibrinated horse 
blood with Skirrows Selective supplement for isolation o f Helicobacter pylori 
Rogosa agar; rogosa agar (Oxoid), 1.32ml/l glacial acetic acid (Sigma-Aldrich 
Chemical Co. Ltd., Poole, England) for isolation o ïLactobacillus spp.
Scliaedler agar; schaedler agar base (Oxoid), with 5% (v/v) defibrinated horse 
blood for anaerobic BTVC and isolation of gram positive anaerobes.
Neomycin agar; schaedler agar base (Oxoid CM 437) with Neomycin 
supplement (Prolab Diagnostics, Neston, Cheshire, UlC), 5% (v/v) defibrinated 
horse blood for gram negative anaerobes.
Veillonella agar; Bacto Veillonella agar (Difco, East Moisey, UK), Vancomycin 
supplement (Prolab) for isolation of Veillonella spp.
Saboiirauds agar (Oxoid) for isolation o f Yeasts.
The aerobic plates were incubated for 48 hours at 37°C in air, the anaerobic 
plates incubated for 72 h at 37°C in an anaerobic jar (BBL anaerobic systems, 
Oxford, UK). The Rogosa agar was incubated at 37"C in 5% CO2 for 5 days. 
Plates for the isolation of H. pylori were incubated microaerophilically at 37^  ^C 
for 5 days (BBL Campypak). Bacteria were identified by standard methods to
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species or genus level as appropriate. Total viable count was determined by a 
total colony count of all bacterial types on blood and anaerobic blood agar.
7.3 Results
Of the 29 subjects recruited for the bacteriology study, 18 had a negative ^^C- 
urea breath test and 11 had a positive breath test. All completed 6 weeks of 
omeprazole.
O f the 32 subjects recnaited for the biochemical study, 5 were excluded after 
incomplete water recovery tests and a further 5 failed to return for the second 
study day. Thus 22 subjects completed the 10 day course of omeprazole; 20 were 
healthy volunteers and 2 had dyspepsia. 10 had a positive ^^C-urea breath test or 
positive CLO test plus H. pylori gastritis, 12 had a negative breath test. All values 
are expressed as medians with range in parentheses.
In tragastric pH (figure 7.1)
Before commencing omeprazole, the intragastric pH of all the H. pylori positive 
and negative subjects from both studies was similar at 1.6( 1.2 - 2 .6) and 1.6(1.2 - 
5,4) respectively. During omeprazole treatment, median intragastric pH was 
elevated in both groups. However, it was elevated to a significantly greater 
degree in the H. pylori positive subjects at 7.8(1.8 - 8.2) compared to 3.0(1.3 -
8 .1 ) in the H. pylori negative subjects, p<0.00001. At 24 hours following the final 
dose o f omeprazole, 95% of the H. pylori positive subjects had a pH>4 compared 
with 40% of the H. pylori negative subjects.
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Gastric juice bacterial counts (figure 7.2)
Before commencing omeprazole, the non-H. pylori flora were not significantly 
different in the H. pylori positive and negative subjects. During omeprazole the 
bacterial count increased in both groups. There were a significantly greater 
number of bacteria, expressed as total viable count (BTVC), in the H. pylori 
positive group compared to the H. pylori negative group [ 6 x 10  ^colony forming 
units (cfli) / ml (0 - 5x10^) versus 5 x 10^  cfu / ml (0 - 6x10^), p<0.05 ]. The 
subjects with the highest intragastric pH during omeprazole therapy had the 
greatest intragastric bacterial counts {(n^28), Spearman correlation coefficient = 
0.846, p<0.002}.
During omeprazole treatment a wide variety of bacterial species were identified in 
both H. pylori positive and negative groups (table 7.1). The most common 
aerobic isolates in both groups were the a-haemolytic or viridans streptococci, 
which predominate in the oral flora. Most of the other aerobic bacteria isolated, 
including Neisseria spp. Haemophihis spp, are typical of the oro-pharyngeal flora 
as opposed to only three isolates of coliforms, which predominate in the aerobic 
colonic flora. In the anaerobic group the most common isolates were VeiUonella 
spp and Bacteroides spp which are part of the anaerobic flora of the entire 
gastrointestinal tract. Both H. pylori positive and negative groups had organisms 
that have been shown to have the ability to reduce nitrate to nitrite (illustrated 
with an asterisk in table 7.1).
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Nitrite
Before omeprazole treatment, the median fasting values for saliva nitrite were 
similar in the H.pylori positive and H.pylori negative groups at 29pmol/L (13 - 
306pmol/L) and 57pmol/L (20-169pmol/L) respectively. Similarly, fasting gastric 
nitrite was largely undetectable at Opmol/L (0 - lOpmol/L) and Opmol/L (0 - 
13pmol/L) respectively. Following the intragastric administration of the nitrate 
meal salivary nitrite levels rose significantly in all subjects, peaking at 20-40 
minutes post ingestion. In H.pylori positive subjects, median salivary nitrite 
peaked at 286|Limol/L (126 - 11 U^mol/L) compared to 498pmol/L (107 - 
774pmol/L) in the H.pylori negative subjects. When the areas under the 
concentration/time curves for saliva nitrite were calculated for each subject, there 
was no difference in the salivary nitrite load between the H.pylori positive and 
H.pylori negative groups [ 26862pmol/L/min (12085 - 115365) vs. 
36325j.Lmol/L/min (16625 - 75010) respectively ]. Despite this marked rise in 
salivary nitrite following the nitrate meal, and therefore increased nitrite delivery 
to the stomach, median gastric nitrite levels remained low. There was no 
difference between the H.pylori positive and negative subjects in post-meal 
gastric nitrite levels, as calculated by the median area under the 
concentration/time curve [670|_imol/L/min (9 - 4900) vs. 1237 pmol/L/min (0 - 
12945), p=NS].
During omeprazole treatment, the salivaiy nitrite load delivered to the stomach 
following the nitrate meal was similar in the H. pylori positive and negative 
subjects -  as measured by the area under the saliva nitrite concentration/time
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curve -  at 37247 pmol/L/min (14315 - 87079 pmol/L/min) and 39637 
!_imol/L/min (14630 - 112610 |Limol/L/min) respectively. The fasting gastric nitrite 
levels in the H. pylori positive and negative groups during omeprazole were 
similar at 7.5pmol/L (0 -  20pmol/L) and 8.5|Limol/L (0 -  24pmol/L) respectively 
and were greater than pre-omeprazole levels in both groups. Following the nitrate 
meal, however, the H. pylori positive subjects showed a significant rise in gastric 
nitrite compared to pre-omeprazole levels, as calculated by the area under the 
gastric nitrite concentration/time curve { median auc: 12450 pmol/L.min (1454 - 
17495) vs. 670 pmol/L.min (9 - 4900) pre-omeprazole, p = 0.006}. In contrast in 
the H. pylori negative subjects there was a positive trend towards an increase in 
gastric nitrite but this failed to reach significance {median auc; 4708|Limol/L.min 
(680 - 13515) vs. 1237pmol/L.min (0 - 12945) pre-omeprazole, p==0.13}. 
Consequently on omeprazole the gastric nitrite levels following the nitrate meal 
were greater in the IT. pylori positive subjects compared to the FI. pylori negative 
subjects (12450 pmol/L.min (1454 - 17495) vs. 4708jLLmol/L.min (680 - 13515), 
p^O.04}(figure 7.3). Taking all the subjects together there was a significant 
positive correlation between intragastric pH during omeprazole and gastric nitrite 
levels following the nitrate meal |(n  = 22) Spearman correlation coefficient = 
0.48, p<0.05}.
Ascorbic acid and total vitamin C
Before commencing omeprazole, the median fasting serum AA in the H.pylori 
positives was 3.1 pg/ml (0.9 - 5.0pg/ml) and serum TVC was 3.4pg/ml (0.9 - 
5.4pg/ml). In the H.pylori negative subjects, the values were similar at 3.6|_ig/ml
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(1.4 - 5.4pg/ml) and 3.6pg/ml (1.4 - 6.5|Lig/ml) respectively. The fasting gastric 
juice AA in the H.pylori positives was 2.0pg/ml (1.3 - 5. Ipg/ml) and gastric TVC 
was 3.7pg/ml (1.7 - 6.2pg/ml) and the values were similar in the H.pylori 
negative subjects at 2.6pg/ml (0.8 - 18.6|Lig/ml) and 4.2pg/ml (1.8 - 19.5pg/ml) 
respectively. Following the intragastric administration of the nitrate meal, the 
gastric AA levels fell in both groups and this coincided with the rise in salivaiy 
nitrite. Gastric TVC levels remained unchanged. There was no difference between 
the H. pylori positive and negative subjects following the nitrate meal with 
respect to AA or TVC.
During omeprazole treatment, fasting gastric TVC levels in the H. pylori positive 
subjects fell from 3.7pg/ml (1.7 - 6.2pg/ml) pre-omeprazole to 1.8pg/ml (0.7- 
3.4pg/ml), p<0.009, but were unchanged in the H. pylori negative subjects at 
3.4pg/ml (1.3 - 14.8|_ig/ml) vs. 4.2pg/ml (1.8 - 19.5pg/ml) pre-omeprazole. 
Consequently during omeprazole treatment gastric juice TVC was significantly 
lower in the H. pylori positives at 1.8 pg/ml (0.7 - 3.4pg/ml) vs. 3.4 (1.3 - 
14.8pg/ml) in the H. pylori negatives, p ^  0.02 (figure 7.4). Following the nitrate 
meal, TVC levels rose over the 2 hours and at 120 minutes post dosing were 
significantly greater than fasting levels in both groups. However, gastric TVC 
levels in H. pylori positive group remained significantly lower than the FI. pylori 
negative group throughout.
Fasting gastric AA levels also fell significantly in the H. pylori positive group on 
omeprazole from 2.0pg/ml (1.3 - 5. Ipg/ml) pre-omeprazole to 1.2|_ig/ml (0 -
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2.4pg/ml), p=0.018, such that AA became undetectable in 5 of the 10 subjects. In 
the H. pylori negative subjects the fall in fasting gastric AA was less marked, 
from 2.6pg/ml (0.8 - 18.6pg/ml) pre-omeprazole to 1.6 pg/ml (0.9 - 8.4pg/ml) 
and was not statistically significant (p=0.13). In this group AA became 
undetectable in 2 of the 12 subjects. Following administration of the nitrate meal, 
gastric AA levels were undetectable at the 60 minute time point in 6 of the 10 H. 
pylori positive subjects versus 3 o f the 12 H. pylori negative subjects (p=NS).
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7,4Figure legends, figures and table
Figure 7.1: The influence of H. pylori status on intragastric pH before and during 
omeprazole. Subjects from the bacteriology and biochemical studies are presented 
together.
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Figure 7.2: The influence of H. pylori status on fasting gastric juice bacterial 
counts (expressed as colony forming units per millilitre) before and during 
omeprazole.
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Figure 7.3: The influence of H. pylori status on gastric juice nitrite levels 
following ingestion of a standard nitrate meal before and during 
omeprazole. Nitrite levels were recorded in each subject over a 2 hour 
period following ingestion of the meal and a nitrite concentration/time curve 
was plotted. Nitrite levels are presented as the area under the 
concentration/time curve (auc).
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Figure 7.4; Influence of H. pylori status on fasting gastric juice total vitamin C 
levels before and during omeprazole.
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Table 7.1 : Bacterial species isolated from H. pylori positive and negative 
volunteers during omeprazole.
H. pylori -ve (n = 18) li. pylori +ve (n =11)
Non-haemolytic streptococcus 3 2
a  - haemolytic streptococcus 14 9
p - haemolytic streptococcus 2 2
Staphylococcus aureus A 3 2
Coagulase negative Staph. A 6 5
H. influenzae A 1 1
Haemophilus spp. A 3 4
Branham el la catthar rails A 1 1
Neisseria spp. A 7 8
Lactobacillus spp. 5 1
Coiynebacterium spp. A 2 1
Lactose Fermenting Coliform A 2 -
Non Lactose Fermenting Coliform * 1 -
Yeast 1 -
Bacteroides spp. 4 7
VeiUonella spp. A 3 6
Clostridium spp A 4 2
Helicobacter pylori - 2
= can reduce nitrate to nitrite
I l l
7.5 Conclusions
This study confirms previous reports (82) that subjects infected with H. pylori 
achieve greater elevation of intragastric pH during omeprazole treatment than 
non-infected subjects. It extends previous work (88) by demonstrating that the 
bacterial colonisation, elevation of intragastric nitrite and depletion o f intragastric 
vitamin C each associated with proton pump inhibitor therapy are more 
pronounced in or confined to H. pylori infected subjects. During proton pump 
inhibitor therapy the alteration of the intragastric milieu to favour bacterial 
synthesis of NOG is therefore more pronounced in H. pylori positive subjects. 
This may be of relevance to the observed trend of increased moderate to severe 
corpus atrophy in H. pylori positive subjects during long term PPI 
therapy(39,40).
The mechanism by which omeprazole produces more profound elevation of 
intragastric pH in H. pylori infected subjects is incompletely understood. Recent 
studies have indicated that it is related to greater inhibition of gastric acid 
secretion rather than the simple neutralisation of the acid by ammonia produced 
by H. pylori (37). PPI therapy causes H. pylori gastritis to extend into the acid 
secreting body region of the stomach and this may impair the Rinctioning of the 
oxyntic mucosa.
It has been known for some time that intragastric pH is the principal determinant 
of the presence and amount of the non-H. pylori gastric bacterial flora (41). A 
major role of gastric acid is to destroy bacteria or other micro-organisms which
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are constantly being ingested. Achlorhydric patients can be infected by a smaller 
inoculum of pathogens such as Salmonella spp (89) and Listeria monocytogenes 
(90) than those with normal levels of acid. In our present study we found that the 
sustained hypochlorhydria produced by omeprazole in 95% of H. pylori positive 
subjects was accompanied by a non-H. pylori bacterial overgrowth which was 
100 fold greater in density than that observed in the H. pylori negative subjects. 
This can be explained by the fact that at 24 hours post dose 60% of the H. pylori 
negative subjects had an intragastric pH<4 at which bacteria would no longer 
survive.
Previous studies have examined bacterial colonisation of the stomach during PPI 
therapy. Sharma et al (57) showed that following 14 days of omeprazole 30mg 
daily the total number of gastric bacteria was 58.6xl0Vl. This study was not 
controlled for H. pylori status but the bacterial counts recorded are even higher 
than our H. pylori positive group. Verdu et al (70) examined the effect of 
omeprazole 20mg daily on H. pylori negative healthy volunteers and showed a 
median total viable count of 3.1x10^ (1.0x10^5,2x10^). These results are 
comparable with our H. pylori negative group and underline the importance that 
H. pylori status has on bacterial counts.
The species of bacteria colonising the stomach during omeprazole treatment were 
similar in the H. pylori positive and negative subjects and were consistent with 
being mainly of orophaiyngeal origin. The types of bacteria found in this study 
are consistent with earlier studies that indicate the predominant flora of the 
achlorhydric stomach are gram positive facultative streptococci. Our study does
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differ in some respects from earlier work in that we found the most common 
anaerobes isolated were Bacteroides spp and not VeiUonella spp, and we isolated 
more Haemophilus spp (91,92). Some of the bacterial species isolated from the 
stomach on omeprazole have been demonstrated previously to be able to convert 
nitrate to nitrite (93) and to synthesise NOC (83,94,95).
We found that the rise in intragastric nitrite levels during omeprazole was 
significantly greater in H. pylori positive individuals. This was most apparent after 
the nitrate meal. The increase in nitrite levels on omeprazole may occur by two 
mechanisms. The first mechanism is related to the enterosalivary recirculation of 
nitrate and its conversion to nitrite by oral bacteria. 25% of absorbed dietary 
nitrate is secreted into saliva and 6% converted to nitrite by bacteria on the 
dorsum of the tongue. This nitrite is then swallowed in the saliva. If the gastric 
juice is acidic and contains ascorbic acid then the nitrite is rapidly removed by 
conversion to NO (58). In the process of converting nitrite to NO, the AA is 
oxidised to DHAA and this explains the fall in AA in gastric juice following the 
nitrate meal and increased deliveiy of nitrite in saliva. Elevation of the intragastric 
pH by omeprazole markedly slows this reaction allowing persistence and 
accumulation of the swallowed nitrite in the stomach. The higher pH in the H. 
pylori positive subjects on omeprazole will impair the removal of nitrite 
swallowed in saliva from gastric juice to a greater degree. The second possible 
mechanism for the elevation of intragastric nitrite on omeprazole is the presence 
of orophaiyngeal organisms in the stomach and their ability to convert nitrate 
swallowed in saliva to nitrite within the stomach. Again, the increased density of
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colonisation of the stomach in the H. pylori positive subjects on omeprazole will 
increase the formation of nitrite within the stomach by this additional mechanism.
Changes in gastric juice vitamin C and AA on omeprazole were also more marked 
in H. pylori positive versus negative subjects. Omeprazole treatment significantly 
lowered the TVC concentration in the H. pylori positive but not negative 
subjects. Consequently, during omeprazole treatment the intragastric 
concentration of TVC both fasting and following the nitrate meal was lower in 
the H. pylori positive versus negative subjects. The fall in AA on omeprazole both 
fasting and following the nitrate meal was again more marked in the H. pylori 
positive subjects. Following the nitrate meal, gastric juice AA became 
undetectable in 60% of the H. pylori positive subjects versus only 25% of the H. 
pylori negative subjects.
Several reasons may explain the more marked change in vitamin C and AA in the 
FI. pylori positive versus negative subjects on omeprazole. During omeprazole 
treatment the inflammation of the gastric mucosa induced by the infection is not 
confined to the antral region of the stomach but extends to the rest o f the 
stomach producing a pangastritis. This more extensive inflammation of the body 
mucosa may impair the ability of the mucosa to secrete AA into the gastric juice. 
In addition the free radicals produced by the inflamed mucosa will oxidise AA to 
DHAA and the latter to irreversible metabolites of the vitamin (59). The more 
marked elevation of intragastric pH on omeprazole in the H. pylori positive 
subjects may also contribute to the greater depletion of TVC as DHAA is less 
stable at this pH and can be converted to irreversible metabolites.
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The more marked depletion of AA in the H. pylori positive subjects on 
omeprazole may be an additional reason for their significantly greater 
accumulation of nitrite. The removal of nitrite from gastric juice by converting it 
to NO is dependent on the presence o f AA in gastric juice as well as the acidity of 
gastric juice. The fact that the H. pylori positive subjects have both a higher 
intragastric pH and lower intragastric AA will predispose to greater accumulation 
of nitrite.
In summaiy, during omeprazole treatment H. pylori positive subjects had a higher 
intragastric pH, greater secondary bacterial colonisation, a greater rise in 
intragastric nitrite and a more marked depletion of gastric juice vitamin C than H. 
pylori negative subjects. These more profound changes may all be a consequence 
of the more marked elevation o f intragastric pH observed in the H. pylori positive 
subjects. However, in an earlier study (88) we examined H. pylori positive and 
negative subjects at 2 hours following completion of a 4 week course of 
omeprazole when the intragastric pH of both groups was similar at pH > 7. On 
that occasion an equivalent rise in gastric nitrite was obsei’ved in both groups. 
However, total vitamin C concentrations fell in the H. pylori positive subjects 
only. This suggests that the changes in vitamin C cannot be explained by the 
change in pH alone but are more likely due to the associated pan-gastritis.
Our studies therefore indicate that changes in the intragastric milieu during PPI 
therapy which predispose to intragastric NOC formation are more marked in H. 
pylori positive versus negative subjects. During omeprazole treatment the H.
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pylori infected subjects had a greater degree of colonisation by bacteria with the 
potential to form NOC, a greater rise in intragastric nitrite and more marked 
depletion of gastric juice TVC. These changes in the intragastric milieu observed 
in H. pylori positive subjects on omeprazole are identical to changes observed in 
patients with H. pylori-induced atrophic gastritis; which is now recognised to be a 
major condition predisposing to gastric cancer (22). The latter subjects have 
elevated intragastric pH, bacterial colonisation, elevated nitrite and depletion of 
vitamin C (29,44-46,96,97).
At present it is unclear whether the development of cancer in patients with H. 
pylori-induced atrophic gastritis is due to the altered intragastric milieu permitting 
intragastric bacterial synthesis of NOC or due to the more direct effects of the 
inflamed mucosa or a combination of the two. It is known that H. pylori infection 
in animals increases their susceptibility to NOC induced cancers (98). H. pylori 
positive subjects on omeprazole have both the altered intragastric milieu 
associated with gastric cancer and the inflamed mucosa and considerable concern 
must exist about the potential long term adverse effects of this combination.
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CHAPTER 8
FINAL DISCUSSION AND CONCLUSIONS
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Achlorhydria is a recognised risk factor for gastric cancer. Correa’s original 
hypothesis for gastric carcinogenesis proposed that the development of atrophic 
gastritis produced achlorhydria and secondary colonisation o f the stomach with 
nitrosating bacteria. These organisms reduce dietary nitrate to nitrite, then 
catalyse the synthesis of potentially carcinogenic N-nitroso compounds (NOC) 
from nitrite and secondary amines present in gastric juice. Vitamin C inhibits 
NOC synthesis. Subsequent work has identified that H. pylori infection can 
produce atrophic gastritis and the World Health Organisation has declared it a 
definite carcinogen.
The development of proton pump inhibitors has greatly enhanced the treatment of 
acid related disorders. They achieve greater acid suppression than H2 antagonists. 
In the presence of co-existing H. pylori infection, they render subjects 
achlorhydric from one dose to the next. This is associated with the development 
of a pangastritis, which in turn is associated with a degree of atrophy. Whether 
this is harmful in the long term remains hotly debated. Two recent reports have 
suggested that long term PPI therapy leads to the development of moderate- 
severe atrophic gastritis. This would place patients at an increased risk of gastric 
cancer.
This thesis examines the intragastric environment produced by PPI’s, paying 
particular attention to the key parameters of dietary nitrate, nitrite and vitamin C 
that are relevant to NOC synthesis. Using novel methodology this work 
ultimately demonstrates that, during omeprazole therapy, subjects infected with
H. pylori experience greater acid suppression, greater bacterial colonisation of the
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stomach, greater gastric nitrite levels than non-inlfected subjects and also suffer 
depletion of gastric vitamin C levels. In combination, these changes to the 
intragastric environment will facilitate intragastric bacterial NOC synthesis.
Further studies are required to confirm that NOC synthesis occurs. Measurement 
of NOC in vivo has been attempted by others and is technically difficult due to 
their volatile nature. Creation of an artificial stomach in which the conditions can 
be manipulated to mimic the in vivo situation is a possible solution. In the interim, 
any patients requiring long term PPI therapy should have any co-existing H. 
pylori infection eradicated.
This work also describes the previously unrecognised chemical reaction that 
occurs in vivo when saliva nitrite meets gastric juice ascorbic acid. This finding 
may be of benefit in understanding the pathophysiology of diseases of the upper 
GI tract, and the gastro-oesophageal junction in particular. Further studies should 
be directed towards measurement of the nitric oxide produced by this reaction 
and its effects. Further studies may also be directed towards examining the 
chemistry within the lumen in other disorders of the GI tract, such as 
inflammatoiy bowel disease, where understanding of the pathophysiology remains 
elusive.
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